CATHYENGCATHY ENG9041ENG, CATHYProfessorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson25069797Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz SClinical colorectal cancerProgression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014 Sep; 13(3):164-71.Clin Colorectal Cancer2014-06-23T00:00:002014Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer.1400 Holcombe BlvdHouston77030-4008TXAuthorship 1731939Authorship 1752226Authorship 17560110Authorship 1761927Authorship 1762438Authorship 1772561Authorship 1789106Authorship 1797819Authorship 1802246Authorship 1812558Authorship 1815621Authorship 1817744Authorship 1825321Authorship 1829533Authorship 1837647Authorship 18429611Authorship 1870687Authorship 1871391Authorship 1871536Authorship 1877895Authorship 19344111Authorship 1936454Authorship 194631215137959Eng C, Abbruzzese J, Minsky BDSurgical oncology clinics of North AmericaChemotherapy and radiation of anal canal cancer: the first approach. Surg Oncol Clin N Am. 2004 Apr; 13(2):309-20, viii.Surg Oncol Clin N Am2004-04-01T00:00:002004Chemotherapy and radiation of anal canal cancer: the first approach.15297392Milano MT, Haraf DJ, Stenson KM, Witt ME, Eng C, Mittal BB, Argiris A, Pelzer H, Kozloff MF, Vokes EEClinical cancer research : an official journal of the American Association for Cancer ResearchPhase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck. Clin Cancer Res. 2004 Aug 01; 10(15):4922-32.Clin Cancer Res2004-08-01T00:00:002004Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck.16755173Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Hoff PM, Eng C, Wolff RA, Janjan NA, Delclos ME, Krishnan S, Levy LB, Ellis LM, Crane CHAmerican journal of clinical oncologyClinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. Am J Clin Oncol. 2006 Jun; 29(3):219-24.Am J Clin Oncol2006-06-01T00:00:002006Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer.16939964Eng CCancer investigationAnal cancer: current and future methodology. Cancer Invest. 2006 Aug-Sep; 24(5):535-44.Cancer Invest2006-08-01T00:00:002006Anal cancer: current and future methodology.17011451Krishnan S, Janjan NA, Skibber JM, Rodriguez-Bigas MA, Wolff RA, Das P, Delclos ME, Chang GJ, Hoff PM, Eng C, Brown TD, Crane CH, Feig BW, Morris J, Vadhan-Raj S, Hamilton SR, Lin EHInternational journal of radiation oncology, biology, physicsPhase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):762-71.Int J Radiat Oncol Biol Phys2006-11-01T00:00:002006Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer.18207667Yu TK, Bhosale PR, Crane CH, Iyer RB, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Eng C, Wolff RA, Janjan NA, Delclos ME, Krishnan S, Das PInternational journal of radiation oncology, biology, physicsPatterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2008 Jul 15; 71(4):1175-80.Int J Radiat Oncol Biol Phys2008-01-22T00:00:002008Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer.19231109Hodges JC, Das P, Eng C, Reish AG, Beddar AS, Delclos ME, Krishnan S, Crane CHInternational journal of radiation oncology, biology, physicsIntensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement. Int J Radiat Oncol Biol Phys. 2009 Nov 01; 75(3):791-4.Int J Radiat Oncol Biol Phys2009-02-21T00:00:002009Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement.19479383Eng C, Pathak PCurrent treatment options in oncologyTreatment options in metastatic squamous cell carcinoma of the anal canal. Curr Treat Options Oncol. 2008 Dec; 9(4-6):400-7.Curr Treat Options Oncol2009-05-29T00:00:002009Treatment options in metastatic squamous cell carcinoma of the anal canal.20067946Eng CThe oncologistThe evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. Oncologist. 2010; 15(1):73-84.Oncologist2010-01-12T00:00:002010The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development.24362907Guo Y, Jones D, Palmer JL, Forman A, Dakhil SR, Velasco MR, Weiss M, Gilman P, Mills GM, Noga SJ, Eng C, Overman MJ, Fisch MJSupportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerOral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer. 2014 May; 22(5):1223-31.Support Care Cancer2013-12-22T00:00:002013Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.24474245Haynes AB, You YN, Hu CY, Eng C, Kopetz ES, Rodriguez-Bigas MA, Skibber JM, Cantor SB, Chang GJCancerPostoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007. Cancer. 2014 Apr 15; 120(8):1162-70.Cancer2014-01-28T00:00:002014Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007.25183707de Carvalho Barbosa M, Kosturakis AK, Eng C, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Wang XS, Cleeland CS, Dougherty PMCancer researchA quantitative sensory analysis of peripheral neuropathy in colorectal cancer and its exacerbation by oxaliplatin chemotherapy. Cancer Res. 2014 Nov 01; 74(21):5955-62.Cancer Res2014-09-02T00:00:002014A quantitative sensory analysis of peripheral neuropathy in colorectal cancer and its exacerbation by oxaliplatin chemotherapy.GI Medical OncologyLeukemiaRadiation OncologySurgical OncologyMD AndersonJAFFER AAJANIJAFFER A AJANI8473AJANI, JAFFER AProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorROBERT AWOLFFROBERT A WOLFF8726WOLFF, ROBERT AProfessorJEAN NICOLASVAUTHEYJEAN NICOLAS VAUTHEY8766VAUTHEY, JEAN NICOLASProfessorPRAJNANDASPRAJNAN DAS9185DAS, PRAJNANProfessor12.0680.00871762578research areas6.253340.0181178189coauthor of410.1662.146460similar to11310selected publicationsMICHAEL JAMESOVERMANMICHAEL JAMES OVERMAN9176OVERMAN, MICHAEL JAMESAssociate ProfessorGEORGE JCHANGGEORGE J CHANG9201CHANG, GEORGE JProfessorAuthorship 2230572Authorship 2238933Authorship 22545010Authorship 2257611Authorship 2257705Authorship 2258142Authorship 2260178Authorship 2260633Authorship 2264369Authorship 2267871Authorship 2268721Authorship 2272248Authorship 2275086Authorship 22761310Authorship 2276376Authorship 2300373Authorship 2300864Authorship 23036611Authorship 2314632Authorship 2315022Authorship 2315196Authorship 2323393Authorship 2324027Authorship 2332702Authorship 23393110Authorship 2343053Authorship 234944216635283Abdalla EK, Eng C, Madary A, Vauthey JN, Southwest Oncology Group 0408Clinical colorectal cancerSouthwest Oncology Group 0408: Phase II trial of neoadjuvant capecitabine/oxaliplatin/bevacizumab for resectable colorectal metastases in the liver. Clin Colorectal Cancer. 2006 Mar; 5(6):436-9.Clin Colorectal Cancer2006-03-01T00:00:002006Southwest Oncology Group 0408: Phase II trial of neoadjuvant capecitabine/oxaliplatin/bevacizumab for resectable colorectal metastases in the liver.17379452Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Bhosale P, Delclos ME, Krishnan S, Janjan NA, Crane CHInternational journal of radiation oncology, biology, physicsPredictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):794-800.Int J Radiat Oncol Biol Phys2007-03-26T00:00:002007Predictors and patterns of recurrence after definitive chemoradiation for anal cancer.18021488Eng CClinical colorectal cancerCombining targeted therapies to enhance the effectiveness of chemotherapy in patients with treatment-refractory colorectal cancer. Clin Colorectal Cancer. 2007 Oct; 6 Suppl 2:S53-9.Clin Colorectal Cancer2007-10-01T00:00:002007Combining targeted therapies to enhance the effectiveness of chemotherapy in patients with treatment-refractory colorectal cancer.18024857Badgwell BD, Camp ER, Feig B, Wolff RA, Eng C, Ellis LM, Cormier JNAnnals of oncology : official journal of the European Society for Medical OncologyManagement of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol. 2008 Mar; 19(3):577-82.Ann Oncol2007-11-16T00:00:002007Management of bevacizumab-associated bowel perforation: a case series and review of the literature.18057297Murthy R, Eng C, Krishnan S, Madoff DC, Habbu A, Canet S, Hicks MEJournal of vascular and interventional radiology : JVIRHepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab. J Vasc Interv Radiol. 2007 Dec; 18(12):1588-91.J Vasc Interv Radiol2007-12-01T00:00:002007Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab.18279578Politano S, Overman M, Pathak P, Chadha R, Glover K, Chang DZ, Wolff RA, Hoff PM, Abbruzzese J, Eng C, Kopetz SClinical colorectal cancerSecond-line chemotherapy use in metastatic colon cancer varies by disease responsiveness. Clin Colorectal Cancer. 2008 Jan; 7(1):55-9.Clin Colorectal Cancer2008-01-01T00:00:002008Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness.18390971Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kr?ning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HAJournal of clinical oncology : official journal of the American Society of Clinical OncologyEPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008 May 10; 26(14):2311-9.J Clin Oncol2008-04-07T00:00:002008EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.18391915Eng CClinical advances in hematology & oncology : H&OK-Ras and sensitivity to EGFR inhibitors in metastatic colorectal cancer. Clin Adv Hematol Oncol. 2008 Mar; 6(3):174-5.Clin Adv Hematol Oncol2008-03-01T00:00:002008K-Ras and sensitivity to EGFR inhibitors in metastatic colorectal cancer.18421052Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, Abbruzzese JL, Eng CJournal of clinical oncology : official journal of the American Society of Clinical OncologySystematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. J Clin Oncol. 2008 Apr 20; 26(12):2000-5.J Clin Oncol2008-04-20T00:00:002008Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.18794067Overman MJ, Fogelman D, Al-Kali A, Crane CH, Evans D, Abdalla EK, Pisters P, Kopetz S, Eng C, Wolff RAClinical colorectal cancerAggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. Clin Colorectal Cancer. 2008 Sep; 7(5):338-42.Clin Colorectal Cancer2008-09-01T00:00:002008Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases.19046131Fogelman DR, Kopetz S, Eng CExpert opinion on emerging drugsEmerging drugs for colorectal cancer. Expert Opin Emerg Drugs. 2008 Dec; 13(4):629-42.Expert Opin Emerg Drugs2008-12-01T00:00:002008Emerging drugs for colorectal cancer.19333227Eng CNature reviews. Clinical oncologyToxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol. 2009 Apr; 6(4):207-18.Nat Rev Clin Oncol2009-04-01T00:00:002009Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer.19475451Lambert LA, Armstrong TS, Lee JJ, Liu S, Katz MH, Eng C, Wolff RA, Tortorice ML, Tansey P, Gonzalez-Moreno S, Lambert DH, Mansfield PFAnnals of surgical oncologyIncidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol. 2009 Aug; 16(8):2181-7.Ann Surg Oncol2009-05-28T00:00:002009Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C.19904805Shapiro JF, Chase JL, Wolff RA, Lambert LA, Mansfield PF, Overman MJ, Ohinata A, Liu J, Wang X, Eng CCancerModern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer. 2010 Jan 15; 116(2):316-22.Cancer2010-01-15T00:00:002010Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience.20041481Das P, Cantor SB, Parker CL, Zampieri JB, Baschnagel A, Eng C, Delclos ME, Krishnan S, Janjan NA, Crane CHCancerLong-term quality of life after radiotherapy for the treatment of anal cancer. Cancer. 2010 Feb 15; 116(4):822-9.Cancer2010-02-15T00:00:002010Long-term quality of life after radiotherapy for the treatment of anal cancer.20886582Pande M, Amos CI, Eng C, Frazier MLMolecular carcinogenesisInteractions between cigarette smoking and selected polymorphisms in xenobiotic metabolizing enzymes in risk for colorectal cancer: A case-only analysis. Mol Carcinog. 2010 Nov; 49(11):974-80.Mol Carcinog2010-11-01T00:00:002010Interactions between cigarette smoking and selected polymorphisms in xenobiotic metabolizing enzymes in risk for colorectal cancer: A case-only analysis.21551253Tanaka M, Chang P, Li Y, Li D, Overman M, Maru DM, Sethi S, Phillips J, Bland GL, Abbruzzese JL, Eng CClinical cancer research : an official journal of the American Association for Cancer ResearchAssociation of CHFR promoter methylation with disease recurrence in locally advanced colon cancer. Clin Cancer Res. 2011 Jul 01; 17(13):4531-40.Clin Cancer Res2011-05-06T00:00:002011Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer.21653683Lieu CH, Lambert LA, Wolff RA, Eng C, Zhang N, Wen S, Rafeeq S, Taggart M, Fournier K, Royal R, Mansfield P, Overman MJAnnals of oncology : official journal of the European Society for Medical OncologySystemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol. 2012 Mar; 23(3):652-658.Ann Oncol2011-06-08T00:00:002011Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix.22421948Garrett CR, Hassabo HM, Bhadkamkar NA, Wen S, Baladandayuthapani V, Kee BK, Eng C, Hassan MMBritish journal of cancerSurvival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer. 2012 Apr 10; 106(8):1374-8.Br J Cancer2012-03-15T00:00:002012Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer.22496202Boyette-Davis JA, Eng C, Wang XS, Cleeland CS, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Zhang H, Dougherty PMClinical cancer research : an official journal of the American Association for Cancer ResearchSubclinical peripheral neuropathy is a common finding in colorectal cancer patients prior to chemotherapy. Clin Cancer Res. 2012 Jun 01; 18(11):3180-7.Clin Cancer Res2012-04-10T00:00:002012Subclinical peripheral neuropathy is a common finding in colorectal cancer patients prior to chemotherapy.22661538Lin M, Gu J, Eng C, Ellis LM, Hildebrandt MA, Lin J, Huang M, Calin GA, Wang D, Dubois RN, Hawk ET, Wu XClinical cancer research : an official journal of the American Association for Cancer ResearchGenetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clin Cancer Res. 2012 Jul 15; 18(14):3982-91.Clin Cancer Res2012-06-01T00:00:002012Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients.22978346Kim DD, Eng CExpert opinion on investigational drugsThe promise of mTOR inhibitors in the treatment of colorectal cancer. Expert Opin Investig Drugs. 2012 Dec; 21(12):1775-88.Expert Opin Investig Drugs2012-09-16T00:00:002012The promise of mTOR inhibitors in the treatment of colorectal cancer.23020527Bilen MA, Taggart MW, Fournier K, Ellis LM, Mansfield PF, Eng C, Royal RE, Overman MJActa oncologica (Stockholm, Sweden)Pathologic complete response in poorly differentiated adenocarcinomas of the appendix: a case series. Acta Oncol. 2013 Jun; 52(5):1044-6.Acta Oncol2012-10-01T00:00:002012Pathologic complete response in poorly differentiated adenocarcinomas of the appendix: a case series.23466576Mitchell MP, Abboud M, Eng C, Beddar AS, Krishnan S, Delclos ME, Crane CH, Das PAmerican journal of clinical oncologyIntensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. Am J Clin Oncol. 2014 Oct; 37(5):461-6.Am J Clin Oncol2014-10-01T00:00:002014Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity.24149137Raghav KP, Shetty AV, Kazmi SM, Zhang N, Morris J, Taggart M, Fournier K, Royal R, Mansfield P, Eng C, Wolff RA, Overman MJThe oncologistImpact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist. 2013; 18(12):1270-7.Oncologist2013-10-22T00:00:002013Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas.24315563Das P, Eng C, Rodriguez-Bigas MA, Chang GJ, Skibber JM, You YN, Maru DM, Munsell MF, Clemons MV, Kopetz SE, Garrett CR, Shureiqi I, Delclos ME, Krishnan S, Crane CHInternational journal of radiation oncology, biology, physicsPreoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. Int J Radiat Oncol Biol Phys. 2014 Feb 01; 88(2):301-5.Int J Radiat Oncol Biol Phys2013-12-05T00:00:002013Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial.24375188Blackham AU, Swett K, Eng C, Sirintrapun J, Bergman S, Geisinger KR, Votanopoulos K, Stewart JH, Shen P, Levine EAJournal of surgical oncologyPerioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2014 Jun; 109(7):740-5.J Surg Oncol2013-12-28T00:00:002013Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.Authorship 2462651Authorship 2467971Authorship 2490341Authorship 2490929Authorship 2492706Authorship 2514732Authorship 2520474Authorship 2522342Authorship 2524031Authorship 2524644Authorship 2533597Authorship 2542993Authorship 2545013Authorship 2548575Authorship 2552422Authorship 2554109Authorship 2562434Authorship 2563927Authorship 2568822Authorship 2569646Authorship 2571734Authorship 2572892Authorship 2575672Authorship 25777911Authorship 2580681Authorship 2592021Authorship 26086814Authorship 2611527Authorship 261545415577433Eng C, Ramanathan RK, Ramathan RK, Wong MK, Remick SC, Dai L, Wade-Oliver KT, Mani S, Kindler HLAmerican journal of clinical oncologyA Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol. 2004 Dec; 27(6):565-9.Am J Clin Oncol2004-12-01T00:00:002004A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma.16163242Eng C, Abbruzzese JLClinical advances in hematology & oncology : H&OThe treatment of colorectal carcinoma: standard chemotherapy and beyond. Clin Adv Hematol Oncol. 2004 Sep; 2(9):592-8.Clin Adv Hematol Oncol2004-09-01T00:00:002004The treatment of colorectal carcinoma: standard chemotherapy and beyond.16805714Eng C, Shalan NExpert opinion on pharmacotherapyBiological agents versus chemotherapy in the treatment of colorectal cancer. Expert Opin Pharmacother. 2006 Jul; 7(10):1251-71.Expert Opin Pharmacother2006-07-01T00:00:002006Biological agents versus chemotherapy in the treatment of colorectal cancer.17056196Das P, Lin EH, Bhatia S, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Hoff PM, Eng C, Wolff RA, Delclos ME, Krishnan S, Janjan NA, Crane CHInternational journal of radiation oncology, biology, physicsPreoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys. 2006 Dec 01; 66(5):1378-83.Int J Radiat Oncol Biol Phys2006-10-23T00:00:002006Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis.17295102Swartz RJ, de Moor C, Cook KF, Fouladi RT, Basen-Engquist K, Eng C, Carmack Taylor CLQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitationMode effects in the center for epidemiologic studies depression (CES-D) scale: personal digital assistant vs. paper and pencil administration. Qual Life Res. 2007 Jun; 16(5):803-13.Qual Life Res2007-02-13T00:00:002007Mode effects in the center for epidemiologic studies depression (CES-D) scale: personal digital assistant vs. paper and pencil administration.18279580Bhaskara A, Eng CClinical colorectal cancerBevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases. Clin Colorectal Cancer. 2008 Jan; 7(1):65-8.Clin Colorectal Cancer2008-01-01T00:00:002008Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases.19047998Eng C, Crane CH, Rodriguez-Bigas MANature clinical practice. Gastroenterology & hepatologyShould cisplatin be avoided in the treatment of locally advanced squamous cell carcinoma of the anal canal? Nat Clin Pract Gastroenterol Hepatol. 2009 Jan; 6(1):16-7.Nat Clin Pract Gastroenterol Hepatol2008-12-02T00:00:002008Should cisplatin be avoided in the treatment of locally advanced squamous cell carcinoma of the anal canal?19147305Herman MP, Kopetz S, Bhosale PR, Eng C, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Delclos ME, Krishnan S, Crane CH, Das PInternational journal of radiation oncology, biology, physicsSacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course. Int J Radiat Oncol Biol Phys. 2009 Jul 01; 74(3):818-23.Int J Radiat Oncol Biol Phys2009-01-13T00:00:002009Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course.19164203Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RAJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 2009 Jun 01; 27(16):2598-603.J Clin Oncol2009-01-21T00:00:002009Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.19464823Crane CH, Eng C, Feig BW, Das P, Skibber JM, Chang GJ, Wolff RA, Krishnan S, Hamilton S, Janjan NA, Maru DM, Ellis LM, Rodriguez-Bigas MAInternational journal of radiation oncology, biology, physicsPhase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):824-30.Int J Radiat Oncol Biol Phys2009-05-21T00:00:002009Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer.19470929Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RRJournal of clinical oncology : official journal of the American Society of Clinical OncologyImproved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009 Aug 01; 27(22):3677-83.J Clin Oncol2009-05-26T00:00:002009Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.19805670Chang GJ, Hu CY, Eng C, Skibber JM, Rodriguez-Bigas MAJournal of clinical oncology : official journal of the American Society of Clinical OncologyPractical application of a calculator for conditional survival in colon cancer. J Clin Oncol. 2009 Dec 10; 27(35):5938-43.J Clin Oncol2009-10-05T00:00:002009Practical application of a calculator for conditional survival in colon cancer.20008624Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JVJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010 Jan 20; 28(3):453-9.J Clin Oncol2009-12-14T00:00:002009Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.20166216Wang XS, Williams LA, Eng C, Mendoza TR, Shah NA, Kirkendoll KJ, Shah PK, Trask PC, Palos GR, Cleeland CSCancerValidation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI). Cancer. 2010 Apr 15; 116(8):2053-63.Cancer2010-04-15T00:00:002010Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI).20564148Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong D, Wheler J, Bedikian AY, Eng C, Wallace M, Camacho LH, Kurzrock RCancerA phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer. 2010 Sep 01; 116(17):4086-94.Cancer2010-09-01T00:00:002010A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver.20665488Tanaka M, Javle M, Dong X, Eng C, Abbruzzese JL, Li DCancerGemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer. 2010 Nov 15; 116(22):5325-35.Cancer2010-11-15T00:00:002010Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.21217399Cheng L, Eng C, Nieman LZ, Kapadia AS, Du XLAmerican journal of clinical oncologyTrends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol. 2011 Dec; 34(6):573-80.Am J Clin Oncol2011-12-01T00:00:002011Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005.21328329Tsai CJ, Crane CH, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Feig BW, Eng C, Krishnan S, Maru DM, Das PCancerNumber of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma. Cancer. 2011 Aug 15; 117(16):3713-22.Cancer2011-02-15T00:00:002011Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma.21826084Aklilu M, Eng CNature reviews. Clinical oncologyThe current landscape of locally advanced rectal cancer. Nat Rev Clin Oncol. 2011 Aug 09; 8(11):649-59.Nat Rev Clin Oncol2011-08-09T00:00:002011The current landscape of locally advanced rectal cancer.22280844Garrett CR, George B, Viswanathan C, Bhadkamkar NA, Wen S, Baladandayuthapani V, You YN, Kopetz ES, Overman MJ, Kee BK, Eng CClinical colorectal cancerSurvival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary. Clin Colorectal Cancer. 2012 Sep; 11(3):191-4.Clin Colorectal Cancer2012-01-26T00:00:002012Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary.22318908Lin M, Eng C, Hawk ET, Huang M, Greisinger AJ, Gu J, Ellis LM, Wu X, Lin JCarcinogenesisGenetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma. Carcinogenesis. 2012 Apr; 33(4):841-7.Carcinogenesis2012-02-08T00:00:002012Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma.22402509Eng CClinical advances in hematology & oncology : H&OCarcinoma of the anal canal: small steps in treatment advances. Clin Adv Hematol Oncol. 2011 Sep; 9(9):662-9.Clin Adv Hematol Oncol2011-09-01T00:00:002011Carcinoma of the anal canal: small steps in treatment advances.22493423Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, Feig BW, Das P, Krishnan S, Crane CH, Hu CY, Chang GJJournal of clinical oncology : official journal of the American Society of Clinical OncologyNeoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012 May 20; 30(15):1770-6.J Clin Oncol2012-04-09T00:00:002012Neoadjuvant treatment response as an early response indicator for patients with rectal cancer.22505654Dai J, Gu J, Huang M, Eng C, Kopetz ES, Ellis LM, Hawk E, Wu XCarcinogenesisGWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis. 2012 Jul; 33(7):1327-31.Carcinogenesis2012-04-12T00:00:002012GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes.22673945Lin M, Eng C, Hawk ET, Huang M, Lin J, Gu J, Ellis LM, Wu XCancerIdentification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma. Cancer. 2012 Dec 15; 118(24):6188-98.Cancer2012-06-06T00:00:002012Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma.23725852Eng CThe Lancet. OncologyWill PICCOLO affect metastatic colorectal cancer therapy? Lancet Oncol. 2013 Jul; 14(8):679-80.Lancet Oncol2013-05-29T00:00:002013Will PICCOLO affect metastatic colorectal cancer therapy?24089344Agarwal A, Chang GJ, Hu CY, Taggart M, Rashid A, Park IJ, You YN, Das P, Krishnan S, Crane CH, Rodriguez-Bigas M, Skibber J, Ellis L, Eng C, Kopetz S, Maru DMCancerQuantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer. 2013 Dec 15; 119(24):4231-41.Cancer2013-10-01T00:00:002013Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy.24143206Lieu CH, Tran H, Jiang ZQ, Mao M, Overman MJ, Lin E, Eng C, Morris J, Ellis L, Heymach JV, Kopetz SPloS oneThe association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One. 2013; 8(10):e77117.PLoS One2013-10-15T00:00:002013The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer.24342822Rogers JE, Ohinata A, Dasari A, Eng CClinical colorectal cancerAtypical metastatic presentations in colorectal cancer: a case series. Clin Colorectal Cancer. 2014 Mar; 13(1):e1-4.Clin Colorectal Cancer2013-11-12T00:00:002013Atypical metastatic presentations in colorectal cancer: a case series.Authorship 2670857Authorship 2682395Authorship 2691877Authorship 2693993Authorship 2696572Authorship 27002417Authorship 2700561Authorship 2700811Authorship 2701528Authorship 27071410Authorship 270845217387743Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA, Eng C, Krishnan S, Janjan NA, Crane CHCancerPredictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer. 2007 May 01; 109(9):1750-5.Cancer2007-05-01T00:00:002007Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer.19399614Ajani JA, Wang X, Izzo JG, Crane CH, Eng C, Skibber JM, Das P, Rashid ADigestive diseases and sciencesMolecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. Dig Dis Sci. 2010 Apr; 55(4):1098-105.Dig Dis Sci2009-04-28T00:00:002009Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation.19673001Chang GJ, Rodriguez-Bigas MA, Eng C, Skibber JMCancerLymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome. Cancer. 2009 Dec 01; 115(23):5432-40.Cancer2009-12-01T00:00:002009Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome.19695792Das P, Delclos ME, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Eng C, Bedi M, Krishnan S, Crane CHInternational journal of radiation oncology, biology, physicsHyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. Int J Radiat Oncol Biol Phys. 2010 May 01; 77(1):60-5.Int J Radiat Oncol Biol Phys2009-08-19T00:00:002009Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation.20720215Eng CScience translational medicineAre herbal medicines ripe for the cancer clinic? Sci Transl Med. 2010 Aug 18; 2(45):45ps41.Sci Transl Med2010-08-18T00:00:002010Are herbal medicines ripe for the cancer clinic?20856734Eng C, Kopetz SJournal of oncology practiceCommentary: practice patterns and potential impact on quality measures for a practicing physician. J Oncol Pract. 2009 Sep; 5(5):233-5.J Oncol Pract2009-09-01T00:00:002009Commentary: practice patterns and potential impact on quality measures for a practicing physician.21557708Garrett CR, Eng CExpert opinion on biological therapyCetuximab in the treatment of patients with colorectal cancer. Expert Opin Biol Ther. 2011 Jul; 11(7):937-49.Expert Opin Biol Ther2011-05-11T00:00:002011Cetuximab in the treatment of patients with colorectal cancer.21748296El-Khoueiry AB, Rankin CJ, Ben-Josef E, Lenz HJ, Gold PJ, Hamilton RD, Govindarajan R, Eng C, Blanke CDInvestigational new drugsSWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs. 2012 Aug; 30(4):1646-51.Invest New Drugs2011-07-12T00:00:002011SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.22180853Pecot CV, Bischoff FZ, Mayer JA, Wong KL, Pham T, Bottsford-Miller J, Stone RL, Lin YG, Jaladurgam P, Roh JW, Goodman BW, Merritt WM, Pircher TJ, Mikolajczyk SD, Nick AM, Celestino J, Eng C, Ellis LM, Deavers MT, Sood AKCancer discoveryA novel platform for detection of CK+ and CK- CTCs. Cancer Discov. 2011 Dec; 1(7):580-6.Cancer Discov2011-11-03T00:00:002011A novel platform for detection of CK+ and CK- CTCs.22512706Richardson PG, Eng C, Kolesar J, Hideshima T, Anderson KCExpert opinion on drug metabolism & toxicologyPerifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol. 2012 May; 8(5):623-33.Expert Opin Drug Metab Toxicol2012-05-01T00:00:002012Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.23196986Liu SV, Lenkiewicz E, Evers L, Holley T, Kiefer J, Ruiz C, Glatz K, Bubendorf L, Demeure MJ, Eng C, Ramanathan RK, Von Hoff DD, Barrett MTPhysical biologyGenomic analysis and selected molecular pathways in rare cancers. Phys Biol. 2012 Dec; 9(6):065004.Phys Biol2012-11-29T00:00:002012Genomic analysis and selected molecular pathways in rare cancers.Authorship 2730242Authorship 2737567Authorship 2741304Authorship 2747511Authorship 2748812Authorship 2749384Authorship 277666115151950Eng C, Kindler HL, Nattam S, Ansari RH, Kasza K, Wade-Oliver K, Vokes EEAnnals of oncology : official journal of the European Society for Medical OncologyA phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann Oncol. 2004 Jun; 15(6):928-32.Ann Oncol2004-06-01T00:00:002004A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer.17491584Malik Z, Eng CClinical advances in hematology & oncology : H&OThe use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer. Clin Adv Hematol Oncol. 2007 Jan; 5(1 Suppl 1):4-7.Clin Adv Hematol Oncol2007-01-01T00:00:002007The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.19841322Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd GD, Dorfman GS, Eng C, Fong Y, Giusti AF, Lu D, Marsland TA, Michelson R, Poston GJ, Schrag D, Seidenfeld J, Benson ABJournal of clinical oncology : official journal of the American Society of Clinical OncologyAmerican Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 2010 Jan 20; 28(3):493-508.J Clin Oncol2009-10-19T00:00:002009American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer.21855043Watkins J, Slade JH, Phan A, Eng C, Weissferdt A, Overman MJClinical colorectal cancerFatal diffuse alveolar damage associated with oxaliplatin administration. Clin Colorectal Cancer. 2011 Sep; 10(3):198-202.Clin Colorectal Cancer2011-04-28T00:00:002011Fatal diffuse alveolar damage associated with oxaliplatin administration.22675625Kim DD, Eng CInternational journal of surgical oncologyThe current state of targeted agents in rectal cancer. Int J Surg Oncol. 2012; 2012:406830.Int J Surg Oncol2012-05-17T00:00:002012The current state of targeted agents in rectal cancer.23001080Overman MJ, Fournier K, Hu CY, Eng C, Taggart M, Royal R, Mansfield P, Chang GJAnnals of surgeryImproving the AJCC/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade. Ann Surg. 2013 Jun; 257(6):1072-8.Ann Surg2013-06-01T00:00:002013Improving the AJCC/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade.24037775Eng C, Chang GJ, You YN, Das P, Xing Y, Delclos M, Wolff RA, Rodriguez-Bigas MA, Skibber J, Ohinata A, Gould S, Phillips J, Crane CHCancerLong-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. Cancer. 2013 Nov 01; 119(21):3769-75.Cancer2013-08-20T00:00:002013Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal.Authorship 2783806Authorship 2786648Authorship 2796736Authorship 2828436Authorship 2829793Authorship 2877804Authorship 2900352Authorship 2902942Authorship 29039811Authorship 2904062Authorship 2904562Authorship 2905047Authorship 2906003Authorship 2907481Authorship 2928251Authorship 2946482Authorship 2970341Authorship 30007610Authorship 3011323Authorship 303605119259318Das P, Crane CH, Eng C, Ajani JAGastrointestinal cancer research : GCRPrognostic factors for squamous cell cancer of the anal canal. Gastrointest Cancer Res. 2008 Jan; 2(1):10-4.Gastrointest Cancer Res2008-01-01T00:00:002008Prognostic factors for squamous cell cancer of the anal canal.19262718Bedi M, Das P, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Eng C, Wolff RA, Janjan NA, Krishnan S, Crane CHGastrointestinal cancer research : GCRCapecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer. Gastrointest Cancer Res. 2007 Mar; 1(2):44-8.Gastrointest Cancer Res2007-03-01T00:00:002007Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer.24133632Skinner HD, Crane CH, Garrett CR, Eng C, Chang GJ, Skibber JM, Rodriguez-Bigas MA, Kelly P, Sandulache VC, Delclos ME, Krishnan S, Das PCancer medicineMetformin use and improved response to therapy in rectal cancer. Cancer Med. 2013 Feb; 2(1):99-107.Cancer Med2013-02-03T00:00:002013Metformin use and improved response to therapy in rectal cancer.24908401Rogers JE, Eng CJournal of gastrointestinal cancerCetuximab in refractory squamous cell carcinoma of the anal canal. J Gastrointest Cancer. 2014 Dec; 45 Suppl 1:198-200.J Gastrointest Cancer2014-12-01T00:00:002014Cetuximab in refractory squamous cell carcinoma of the anal canal.24919569Van Cutsem E, Eng C, Nowara E, Swieboda-Sadlej A, Tebbutt NC, Mitchell E, Davidenko I, Stephenson J, Elez E, Prenen H, Deng H, Tang R, McCaffery I, Oliner KS, Chen L, Gansert J, Loh E, Smethurst D, Tabernero JClinical cancer research : an official journal of the American Association for Cancer ResearchRandomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clin Cancer Res. 2014 Aug 15; 20(16):4240-50.Clin Cancer Res2014-06-11T00:00:002014Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.24981728Eng C, Ahmed SExpert review of anticancer therapyOptimal management of squamous cell carcinoma of the anal canal: where are we now? Expert Rev Anticancer Ther. 2014 Aug; 14(8):877-86.Expert Rev Anticancer Ther2014-07-01T00:00:002014Optimal management of squamous cell carcinoma of the anal canal: where are we now?25002720Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, Saltz L, Goldberg RM, Sargent DJ, Eckhardt SG, Eng C, Aide et Recherche en Canc?rologie Digestive FoundationJournal of clinical oncology : official journal of the American Society of Clinical OncologyAssociation of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. J Clin Oncol. 2014 Sep 20; 32(27):2975-84.J Clin Oncol2014-09-20T00:00:002014Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program.25008956Ahmed S, Eng CCurrent treatment options in oncologyOptimal treatment strategies for anal cancer. Curr Treat Options Oncol. 2014 Sep; 15(3):443-55.Curr Treat Options Oncol2014-09-01T00:00:002014Optimal treatment strategies for anal cancer.25009008Morris VK, Lucas FAS, Overman MJ, Eng C, Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru D, Scheet P, Kopetz S, Vilar EAnnals of oncology : official journal of the European Society for Medical OncologyClinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Ann Oncol. 2014 Oct; 25(10):2008-2014.Ann Oncol2014-07-09T00:00:002014Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer.25031942Silva NN, Eng CJournal of the advanced practitioner in oncologyManagement of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy. J Adv Pract Oncol. 2012 May; 3(3):161-9.J Adv Pract Oncol2012-05-01T00:00:002012Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy.25051371Subbiah IM, Blackmon SH, Correa AM, Kee B, Vaporciyan AA, Swisher SG, Eng COncotargetPreoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma. Oncotarget. 2014 Aug 30; 5(16):6584-93.Oncotarget2014-08-30T00:00:002014Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma.25089219Law L, Rogers J, Eng CJournal of the advanced practitioner in oncologyDelayed Presentation of DPD Deficiency in Colorectal Cancer. J Adv Pract Oncol. 2014 May; 5(3):205-10.J Adv Pract Oncol2014-05-01T00:00:002014Delayed Presentation of DPD Deficiency in Colorectal Cancer.25373735Eng C, Chang GJ, You YN, Das P, Rodriguez-Bigas M, Xing Y, Vauthey JN, Rogers JE, Ohinata A, Pathak P, Sethi S, Phillips JK, Crane CH, Wolff RAOncotargetThe role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget. 2014 Nov 30; 5(22):11133-42.Oncotarget2014-11-30T00:00:002014The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.25535726Pereira AA, Rego JF, Morris V, Overman MJ, Eng C, Garrett CR, Boutin AT, Ferrarotto R, Lee M, Jiang ZQ, Hoff PM, Vauthey JN, Vilar E, Maru D, Kopetz SBritish journal of cancerAssociation between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer. 2015 Feb 03; 112(3):424-8.Br J Cancer2014-12-23T00:00:002014Association between KRAS mutation and lung metastasis in advanced colorectal cancer.25542058Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, Roth A, Fortpied C, Eng C, Peckitt C, Coens C, Pettaway C, Arnold D, Hall E, Marshall E, Sclafani F, Hatcher H, Earl H, Ray-Coquard I, Paul J, Blay JY, Whelan J, Panageas K, Wheatley K, Harrington K, Licitra L, Billingham L, Hensley M, McCabe M, Patel PM, Carvajal R, Wilson R, Glynne-Jones R, McWilliams R, Leyvraz S, Rao S, Nicholson S, Filiaci V, Negrouk A, Lacombe D, Dupont E, Pauport? I, Welch JJ, Law K, Trimble T, Seymour MEuropean journal of cancer (Oxford, England : 1990)Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. Eur J Cancer. 2015 Feb; 51(3):271-81.Eur J Cancer2014-12-24T00:00:002014Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative.25582740Choe JH, Overman MJ, Fournier KF, Royal RE, Ohinata A, Rafeeq S, Beaty K, Phillips JK, Wolff RA, Mansfield PF, Eng CAnnals of surgical oncologyImproved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms. Ann Surg Oncol. 2015 Aug; 22(8):2578-84.Ann Surg Oncol2015-01-13T00:00:002015Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms.25745054Overman MJ, Eng C, Raghav K, Matamoros A, Taggart M, Foo WC, Fournier KThe oncologistChallenges of efficacy assessments in pseudomyxoma peritonea. Oncologist. 2015 Mar; 20(3):e3-4.Oncologist2015-03-01T00:00:002015Challenges of efficacy assessments in pseudomyxoma peritonea.25806815Kneuertz PJ, Chang GJ, Hu CY, Rodriguez-Bigas MA, Eng C, Vilar E, Skibber JM, Feig BW, Cormier JN, You YNJAMA surgeryOvertreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. JAMA Surg. 2015 May; 150(5):402-9.JAMA Surg2015-05-01T00:00:002015Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains.25993140Eng C, Roach N, Longabaugh M, Fisher GAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual MeetingPerspectives on clinical trials for gastrointestinal malignancies. Am Soc Clin Oncol Educ Book. 2015; 40-3.Am Soc Clin Oncol Educ Book2015-01-01T00:00:002015Perspectives on clinical trials for gastrointestinal malignancies.26184521Eng CThe Lancet. OncologyCirculating DNA biomarkers: a primer for metastatic colorectal cancer? Lancet Oncol. 2015 Aug; 16(8):878-9.Lancet Oncol2015-07-13T00:00:002015Circulating DNA biomarkers: a primer for metastatic colorectal cancer?26382740Morris VK, Rashid A, Rodriguez-Bigas M, Das P, Chang G, Ohinata A, Rogers J, Crane C, Wolff RA, Eng CThe oncologistClinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. Oncologist. 2015 Nov; 20(11):1247-52.Oncologist2015-09-17T00:00:002015Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal.26487956Rogers JE, Silva NN, Eng CJournal of gastrointestinal oncologyCetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal. J Gastrointest Oncol. 2015 Oct; 6(5):E82-5.J Gastrointest Oncol2015-10-01T00:00:002015Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal.15519780Bonnen M, Crane C, Vauthey JN, Skibber J, Delclos ME, Rodriguez-Bigas M, Hoff PM, Lin E, Eng C, Wong A, Janjan NA, Feig BWInternational journal of radiation oncology, biology, physicsLong-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients. Int J Radiat Oncol Biol Phys. 2004 Nov 15; 60(4):1098-105.Int J Radiat Oncol Biol Phys2004-11-15T00:00:002004Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients.74Professor10Assistant Professor14Associate ProfessorVAN KARLYLEMORRISVAN KARLYLE MORRIS11833MORRIS, VAN KARLYLEAssistant Professor20686401Tan CH, Bhosale PR, Das P, Crane CH, Viswanathan C, Raval B, Eng C, Iyer RBAmerican journal of clinical oncologyMultidetector computed tomography follow-up of hypoattenuating small liver lesions in patients with rectal cancer. Am J Clin Oncol. 2011 Aug; 34(4):411-6.Am J Clin Oncol2011-08-01T00:00:002011Multidetector computed tomography follow-up of hypoattenuating small liver lesions in patients with rectal cancer.Authorship 3745063Authorship 3745129Authorship 3747795Authorship 3747824Authorship 3747831117849166Chun YS, Vauthey JN, Ribero D, Donadon M, Mullen JT, Eng C, Madoff DC, Chang DZ, Ho L, Kopetz S, Wei SH, Curley SA, Abdalla EKJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary TractSystemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival. J Gastrointest Surg. 2007 Nov; 11(11):1498-504; discussion 1504-5.J Gastrointest Surg2007-09-11T00:00:002007Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival.19617747Chang GJ, Gonzalez RJ, Skibber JM, Eng C, Das P, Rodriguez-Bigas MADiseases of the colon and rectumA twenty-year experience with adenocarcinoma of the anal canal. Dis Colon Rectum. 2009 Aug; 52(8):1375-80.Dis Colon Rectum2009-08-01T00:00:002009A twenty-year experience with adenocarcinoma of the anal canal.20552409Silberfein EJ, Kattepogu KM, Hu CY, Skibber JM, Rodriguez-Bigas MA, Feig B, Das P, Krishnan S, Crane C, Kopetz S, Eng C, Chang GJAnnals of surgical oncologyLong-term survival and recurrence outcomes following surgery for distal rectal cancer. Ann Surg Oncol. 2010 Nov; 17(11):2863-9.Ann Surg Oncol2010-06-15T00:00:002010Long-term survival and recurrence outcomes following surgery for distal rectal cancer.20406923Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Pathak P, Eng C, Hoff PM, Vauthey JN, Wolff RA, Kopetz SJournal of clinical oncology : official journal of the American Society of Clinical OncologyOxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010 May 20; 28(15):2549-55.J Clin Oncol2010-04-20T00:00:002010Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.Authorship 841128Authorship 841171Authorship 842732Authorship 843980Authorship 844780Authorship 846600Authorship 846927Authorship 847172Authorship 847777Authorship 848659Authorship 848866Authorship 850542Authorship 851449Authorship 852161Authorship 852782Authorship 853179Authorship 855254Authorship 855776Authorship 856258Authorship 856429Authorship 856555Authorship 856997Authorship 857028Authorship 857613Authorship 858709Authorship 858923Authorship 859513Authorship 859527Authorship 860034Authorship 860568Authorship 860849Authorship 861705Authorship 863677Authorship 864807Authorship 865181Authorship 866112Authorship 866190Authorship 867419Annals of OncologyCharacterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Annals of Oncology. 26:731-736.Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatmentBritish Journal of SurgeryImpact of multimodal therapy in locally recurrent rectal cancer. British Journal of Surgery. 103:753-762.Impact of multimodal therapy in locally recurrent rectal cancerAnnals of Surgical OncologyTransthoracic Port Placement Increases Safety of Total Laparoscopic Posterior Sectionectomy. Annals of Surgical Oncology. 1.Transthoracic Port Placement Increases Safety of Total Laparoscopic Posterior SectionectomyColon cancer. 77-84.Colon cancerJournal of Clinical OncologyAmerican society of clinical oncology statement. Journal of Clinical Oncology. 34:1803-1812.American society of clinical oncology statementColorectal cancer survivorship management. 71-93.Colorectal cancer survivorship managementAmerican Journal of Clinical Oncology: Cancer Clinical TrialsOncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials. Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation TherapySurgical Oncology Clinics of North AmericaMetastatic Anal Cancer and Novel Agents. Surgical Oncology Clinics of North America. 26:133-142.Metastatic Anal Cancer and Novel AgentsAnti-Cancer DrugsEpidermal growth factor receptor inhibition in metastatic anal cancer. Anti-Cancer Drugs. 27:804-808.Epidermal growth factor receptor inhibition in metastatic anal cancerRadiotherapy and OncologyHyperfractionated accelerated reirradiation for rectal cancer. Radiotherapy and Oncology. Hyperfractionated accelerated reirradiation for rectal cancerGastrointestinal Cancer ResearchDefinitive chemoradiation in oligometastatic squamous cell carcinoma of the anal canal. Gastrointestinal Cancer Research. 7:65-68.Definitive chemoradiation in oligometastatic squamous cell carcinoma of the anal canalJournal of Gastrointestinal OncologyCetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal. Journal of Gastrointestinal Oncology. 6:E82-E85.Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canalCurrent Colorectal Cancer ReportsClinical implications of circulating tumor cells in advanced colorectal cancer. Current Colorectal Cancer Reports. 8:233-242.Clinical implications of circulating tumor cells in advanced colorectal cancerAmerican Journal of Clinical Oncology: Cancer Clinical TrialsHyperfractionated Accelerated Reirradiation for Patients With Recurrent Anal Cancer Previously Treated With Definitive Chemoradiation. American Journal of Clinical Oncology: Cancer Clinical Trials. Hyperfractionated Accelerated Reirradiation for Patients With Recurrent Anal Cancer Previously Treated With Definitive ChemoradiationActa OncologicaPathologic complete response in poorly differentiated adenocarcinomas of the appendix. Acta Oncologica. 52:1046-1048.Pathologic complete response in poorly differentiated adenocarcinomas of the appendixCancer of the anal region. Cancer of the anal regionIndian Journal of Surgical OncologyPotential Prognostic Impact of Baseline CEA Level and Surgery of Primary Tumor Among Patients with Synchronous Stage IV Colorectal Cancer. Indian Journal of Surgical Oncology. 6:198-206.Potential Prognostic Impact of Baseline CEA Level and Surgery of Primary Tumor Among Patients with Synchronous Stage IV Colorectal CancerOncologistThe treatment of colorectal cancer during pregnancy. Oncologist. 21:563-570.The treatment of colorectal cancer during pregnancyAmerican Journal of Clinical Oncology: Cancer Clinical TrialsErratum. American Journal of Clinical Oncology: Cancer Clinical Trials. 28:455.ErratumOncotargetSerum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancer. Oncotarget. 7:76250-76260.Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancerThe Lancet Gastroenterology and HepatologyPOLE mutations in colorectal cancer. The Lancet Gastroenterology and Hepatology. 1:176-177.POLE mutations in colorectal cancerSurgical Oncology Clinics of North AmericaPreface. Surgical Oncology Clinics of North America. PrefaceInvestigational New DrugsPhase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Investigational New Drugs. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancerBMC CancerRetreatment with anti-EGFR based therapies in metastatic colorectal cancer. BMC Cancer. 15.Retreatment with anti-EGFR based therapies in metastatic colorectal cancerOncotargetMET amplification in metastatic colorectal cancer. Oncotarget. 7:54627-54631.MET amplification in metastatic colorectal cancerDiseases of the Colon and RectumLong-Term results of weekly/daily cisplatin-Based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. Diseases of the Colon and Rectum. 57.Long-Term results of weekly/daily cisplatin-Based chemoradiation for locally advanced squamous cell carcinoma of the anal canalSeminars in Colon and Rectal SurgeryMultidisciplinary management of stage IV colon cancer. Seminars in Colon and Rectal Surgery. Multidisciplinary management of stage IV colon cancerColon, rectal, and anal cancer management. 711-739.Colon, rectal, and anal cancer managementOncology (Switzerland)Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer. Oncology (Switzerland). Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal CancerAmerican Journal of Clinical Oncology: Cancer Clinical TrialsDefinitive Chemoradiation for Squamous Cell Carcinoma of the Rectum. American Journal of Clinical Oncology: Cancer Clinical Trials. Definitive Chemoradiation for Squamous Cell Carcinoma of the RectumAnnals of Surgical OncologyTotal Transthoracic Approach Facilitates Laparoscopic Hepatic Resection in Patients with Significant Prior Abdominal Surgery. Annals of Surgical Oncology. 1-2.Total Transthoracic Approach Facilitates Laparoscopic Hepatic Resection in Patients with Significant Prior Abdominal SurgeryHematology/Oncology Clinics of North AmericaCurrent and emerging trends in the treatment of metastatic colorectal cancer. Hematology/Oncology Clinics of North America. 21:8-17.Current and emerging trends in the treatment of metastatic colorectal cancerColorectal Cancer. 86-136.Colorectal CancerAnnals of Surgical OncologyLow-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UMP). Annals of Surgical Oncology. 1-7.Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UMP)American Journal of Clinical Oncology: Cancer Clinical TrialsIntensity-modulated radiation therapy with concurrent chemotherapy for anal cancer outcomes and toxicity. American Journal of Clinical Oncology: Cancer Clinical Trials. 37:461-466.Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer outcomes and toxicityOncologyBuilding on the foundation of 5-FU to treat metastatic colorectal cancer. Oncology. 22:462-468.Building on the foundation of 5-FU to treat metastatic colorectal cancerAnnals of OncologyUtility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Annals of Oncology. 27:1068-1074.Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trialsOncotargetPhase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer. Oncotarget. 7:67495-67506.Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer28767562Chun YS, Passot G, Yamashita S, Nusrat M, Katsonis P, Loree JM, Conrad C, Tzeng CD, Xiao L, Aloia TA, Eng C, Kopetz SE, Lichtarge O, Vauthey JNAnnals of surgeryDeleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases. Ann Surg. 2019 05; 269(5):917-923.Ann Surg2019-05-01T00:00:002019Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases.29447061Hwang JP, Lok AS, Fisch MJ, Cantor SB, Barbo A, Lin HY, Foreman JT, Vierling JM, Torres HA, Granwehr BP, Miller E, Eng C, Simon GR, Ahmed S, Ferrajoli A, Romaguera J, Suarez-Almazor MEJournal of clinical oncology : official journal of the American Society of Clinical OncologyModels to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study. J Clin Oncol. 2018 Apr 01; 36(10):959-967.J Clin Oncol2018-02-15T00:00:002018Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study.29698419Pande M, Joon A, Brewster AM, Chen WV, Hopper JL, Eng C, Shete S, Casey G, Schumacher F, Lin Y, Harrison TA, White E, Ahsan H, Andrulis IL, Whittemore AS, John EM, Ko Win A, Makalic E, Schmidt DF, Kapuscinski MK, Ochs-Balcom HM, Gallinger S, Jenkins MA, Newcomb PA, Lindor NM, Peters U, Amos CI, Lynch PMPloS oneGenetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies. PLoS One. 2018; 13(4):e0196245.PLoS One2018-04-26T00:00:002018Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies.Authorship 88909412Authorship 88968511Authorship 8902346D001005Disorders1254510.688333Anus NeoplasmsD012004Disorders23411920.54186Rectal NeoplasmsD001063Disorders672320.803625Appendiceal NeoplasmsD015179Disorders68335630.327321Colorectal NeoplasmsD002294Disorders79254500.312453Carcinoma, Squamous CellAuthorship 9032578Authorship 90720515Authorship 9076305Authorship 9077895Authorship 9086055Authorship 9091754Authorship 9093233Authorship 9095757Authorship 9096922Authorship 9097972Authorship 9102954Authorship 9103231Authorship 9113809Authorship 91252216Authorship 9137338Authorship 9141033Authorship 9143688Authorship 9155596Authorship 9157402Authorship 91712113Authorship 91763429Authorship 9176702Authorship 91804111Authorship 91821012Authorship 91856617Authorship 9191327Authorship 91947812Authorship 9197092Authorship 9211064Authorship 9211771Authorship 9213516Authorship 9215444Authorship 9217518Authorship 92179111Authorship 9219116Authorship 9219469Authorship 9222757Authorship 9223082Authorship 9233682Authorship 9235579Authorship 92498010Authorship 92500116Authorship 92604119Authorship 92606310Authorship 92628111Authorship 9270591Authorship 9276059Authorship 9284558Authorship 9285122Authorship 9330597Authorship 9339933Authorship 9351222Authorship 9358501Authorship 9374382Authorship 9378354Authorship 9392351025222072Sturgeon JD, Crane CH, Krishnan S, Minsky BD, Skibber JM, Rodriguez-Bigas MA, Chang GJ, You YN, Eng C, Das PAmerican journal of clinical oncologyDefinitive Chemoradiation for Squamous Cell Carcinoma of the Rectum. Am J Clin Oncol. 2017 Apr; 40(2):163-166.Am J Clin Oncol2017-04-01T00:00:002017Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum.26891420Eng C, Bessudo A, Hart LL, Severtsev A, Gladkov O, M?ller L, Kopp MV, Vladimirov V, Langdon R, Kotiv B, Barni S, Hsu C, Bolotin E, von Roemeling R, Schwartz B, Bendell JCInternational journal of cancerA randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy. Int J Cancer. 2016 Jul 01; 139(1):177-86.Int J Cancer2016-03-22T00:00:002016A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.26882477Wang XS, Shi Q, Dougherty PM, Eng C, Mendoza TR, Williams LA, Fogelman DR, Cleeland CSOncologyPrechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer. Oncology. 2016; 90(3):127-35.Oncology2016-02-17T00:00:002016Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer.27000464Rogers JE, Dasari A, Eng CThe oncologistThe Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges. Oncologist. 2016 05; 21(5):563-70.Oncologist2016-03-21T00:00:002016The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges.27028350Park IJ, You YN, Skibber JM, Rodriguez-Bigas MA, Das P, Eng C, Kopetz S, Wolff RA, Crane CH, Krishnan S, Minsky B, Hu CY, Nguyen S, Chang GJAmerican journal of clinical oncologyOncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. Am J Clin Oncol. 2017 Jun; 40(3):277-282.Am J Clin Oncol2017-06-01T00:00:002017Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy.27217664Dawood S, Sirohi B, Shrikhande SV, Toh HC, Eng CIndian journal of surgical oncologyPotential Prognostic Impact of Baseline CEA Level and Surgery of Primary Tumor Among Patients with Synchronous Stage IV Colorectal Cancer: A Large Population Based Study. Indian J Surg Oncol. 2015 Sep; 6(3):198-206.Indian J Surg Oncol2015-06-07T00:00:002015Potential Prognostic Impact of Baseline CEA Level and Surgery of Primary Tumor Among Patients with Synchronous Stage IV Colorectal Cancer: A Large Population Based Study.27069078Bailey HH, Chuang LT, duPont NC, Eng C, Foxhall LE, Merrill JK, Wollins DS, Blanke CDJournal of clinical oncology : official journal of the American Society of Clinical OncologyAmerican Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention. J Clin Oncol. 2016 05 20; 34(15):1803-12.J Clin Oncol2016-04-11T00:00:002016American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention.27272412Rogers JE, Ohinata A, Silva NN, Mehdizadeh A, Eng CAnti-cancer drugsEpidermal growth factor receptor inhibition in metastatic anal cancer. Anticancer Drugs. 2016 09; 27(8):804-8.Anticancer Drugs2016-09-01T00:00:002016Epidermal growth factor receptor inhibition in metastatic anal cancer.27421137Raghav K, Morris V, Tang C, Morelli P, Amin HM, Chen K, Manyam GC, Broom B, Overman MJ, Shaw K, Meric-Bernstam F, Maru D, Menter D, Ellis LM, Eng C, Hong D, Kopetz SOncotargetMET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. 2016 08 23; 7(34):54627-54631.Oncotarget2016-08-23T00:00:002016MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon.27660258Fournier K, Rafeeq S, Taggart M, Kanaby P, Ning J, Chen HC, Overman M, Raghav K, Eng C, Mansfield P, Royal RAnnals of surgical oncologyLow-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UMP): Prognostic Factors and Implications for Treatment and Follow-up. Ann Surg Oncol. 2017 Jan; 24(1):187-193.Ann Surg Oncol2016-09-22T00:00:002016Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UMP): Prognostic Factors and Implications for Treatment and Follow-up.27747086Morris V, Eng CJournal of gastrointestinal oncologySummary of emerging targets in anal cancer: the case for an immunotherapy based-approach. J Gastrointest Oncol. 2016 Oct; 7(5):721-726.J Gastrointest Oncol2016-10-01T00:00:002016Summary of emerging targets in anal cancer: the case for an immunotherapy based-approach.27755060Osborne EM, Eng C, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Nancy You YQ, Bednarski BK, Minsky BD, Delclos ME, Koay E, Krishnan S, Crane CH, Das PAmerican journal of clinical oncologyHyperfractionated Accelerated Reirradiation for Patients With Recurrent Anal Cancer Previously Treated With Definitive Chemoradiation. Am J Clin Oncol. 2018 07; 41(7):632-637.Am J Clin Oncol2018-07-01T00:00:002018Hyperfractionated Accelerated Reirradiation for Patients With Recurrent Anal Cancer Previously Treated With Definitive Chemoradiation.27878479Yamashita S, Loyer E, Kang HC, Aloia TA, Chun YS, Mehran RJ, Eng C, Lee JE, Vauthey JN, Conrad CAnnals of surgical oncologyTotal Transthoracic Approach Facilitates Laparoscopic Hepatic Resection in Patients with Significant Prior Abdominal Surgery. Ann Surg Oncol. 2017 May; 24(5):1376-1377.Ann Surg Oncol2016-11-22T00:00:002016Total Transthoracic Approach Facilitates Laparoscopic Hepatic Resection in Patients with Significant Prior Abdominal Surgery.27889032Morris V, Eng CSurgical oncology clinics of North AmericaMetastatic Anal Cancer and Novel Agents. Surg Oncol Clin N Am. 2017 01; 26(1):133-142.Surg Oncol Clin N Am2017-01-01T00:00:002017Metastatic Anal Cancer and Novel Agents.27889042Eng CSurgical oncology clinics of North AmericaPreface. Surg Oncol Clin N Am. 2017 01; 26(1):xv-xvi.Surg Oncol Clin N Am2016-10-25T00:00:002016Preface.28057329Tao R, Tsai CJ, Jensen G, Eng C, Kopetz S, Overman MJ, Skibber JM, Rodriguez-Bigas M, Chang GJ, You YN, Bednarski BK, Minsky BD, Delclos ME, Koay E, Krishnan S, Crane CH, Das PRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyHyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. Radiother Oncol. 2017 01; 122(1):146-151.Radiother Oncol2017-01-03T00:00:002017Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity.28267766Mehrvarz Sarshekeh A, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz SPloS oneAssociation of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One. 2017; 12(3):e0173345.PLoS One2017-03-07T00:00:002017Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer.27788488Liu C, Eng C, Shen J, Lu Y, Takata Y, Mehdizadeh A, Chang GJ, Rodriguez-Bigas MA, Li Y, Chang P, Mao Y, Hassan MM, Wang F, Li DOncotargetSerum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancer. Oncotarget. 2016 Nov 15; 7(46):76250-76260.Oncotarget2016-11-15T00:00:002016Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancer.27542211Overman MJ, Morris V, Moinova H, Manyam G, Ensor J, Lee MS, Eng C, Kee B, Fogelman D, Shroff RT, LaFramboise T, Mazard T, Feng T, Hamilton S, Broom B, Lutterbaugh J, Issa JP, Markowitz SD, Kopetz SOncotargetPhase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget. 2016 Oct 11; 7(41):67495-67506.Oncotarget2016-10-11T00:00:002016Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin.28097239Zuo X, Xu W, Xu M, Tian R, Moussalli MJ, Mao F, Zheng X, Wang J, Morris JS, Gagea M, Eng C, Kopetz S, Maru DM, Rashid A, Broaddus R, Wei D, Hung MC, Sood AK, Shureiqi IJCI insightMetastasis regulation by PPARD expression in cancer cells. JCI Insight. 2017 01 12; 2(1):e91419.JCI Insight2017-01-12T00:00:002017Metastasis regulation by PPARD expression in cancer cells.28223062Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng CThe Lancet. OncologyNivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 04; 18(4):446-453.Lancet Oncol2017-02-18T00:00:002017Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.28280091Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz SClinical cancer research : an official journal of the American Association for Cancer ResearchDual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2017 Aug 01; 23(15):4146-4154.Clin Cancer Res2017-03-09T00:00:002017Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer.28291710Zhao L, Chang DW, Gong Y, Eng C, Wu XDNA repairMeasurement of DNA damage in peripheral blood by the ?-H2AX assay as predictor of colorectal cancer risk. DNA Repair (Amst). 2017 05; 53:24-30.DNA Repair (Amst)2017-03-06T00:00:002017Measurement of DNA damage in peripheral blood by the ?-H2AX assay as predictor of colorectal cancer risk.28422758Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GSJCI insightFirst-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight. 2017 Apr 20; 2(8).JCI Insight2017-04-20T00:00:002017First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.28424412Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari AOncotargetFBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget. 2017 Jun 13; 8(24):39268-39279.Oncotarget2017-06-13T00:00:002017FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma.28257146Prinsloo S, Novy D, Driver L, Lyle R, Ramondetta L, Eng C, McQuade J, Lopez G, Cohen LCancerRandomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: A pilot study. Cancer. 2017 06 01; 123(11):1989-1997.Cancer2017-03-03T00:00:002017Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: A pilot study.28404085Eng CThe lancet. Gastroenterology & hepatologyPOLE mutations in colorectal cancer: a new biomarker? Lancet Gastroenterol Hepatol. 2016 11; 1(3):176-177.Lancet Gastroenterol Hepatol2016-07-20T00:00:002016POLE mutations in colorectal cancer: a new biomarker?28518219Hwang JP, Suarez-Almazor ME, Cantor SB, Barbo A, Lin HY, Ahmed S, Chavez-MacGregor M, Donato-Santana C, Eng C, Ferrajoli A, Fisch MJ, McLaughlin P, Simon GR, Rondon G, Shpall EJ, Lok ASCancerImpact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. Cancer. 2017 Sep 01; 123(17):3367-3376.Cancer2017-05-18T00:00:002017Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy.28506255Uemura M, Qiao W, Fournier K, Morris J, Mansfield P, Eng C, Royal RE, Wolff RA, Raghav K, Mann GN, Overman MJBMC cancerRetrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery. BMC Cancer. 2017 05 15; 17(1):331.BMC Cancer2017-05-15T00:00:002017Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery.28510798You YN, Shiozaki H, Lee JE, Passot G, Goumard C, Okuno M, Aloia TA, Eng C, Chang G, Vauthey JN, Conrad CAnnals of surgical oncologyTotal Laparoscopic Management for Stage IV Colorectal Cancer Requiring Multivisceral Resection. Ann Surg Oncol. 2017 Sep; 24(9):2595.Ann Surg Oncol2017-05-16T00:00:002017Total Laparoscopic Management for Stage IV Colorectal Cancer Requiring Multivisceral Resection.28936799Clarke CN, Lee MS, Wei W, Manyam G, Jiang ZQ, Lu Y, Morris J, Broom B, Menter D, Vilar-Sanchez E, Raghav K, Eng C, Chang GJ, Simon I, Bernards R, Overman M, Mills GB, Maru D, Kopetz SAnnals of surgical oncologyProteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. Ann Surg Oncol. 2017 Dec; 24(13):4051-4058.Ann Surg Oncol2017-09-21T00:00:002017Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival.28784613Morris V, Rao X, Pickering C, Foo WC, Rashid A, Eterovic K, Kim T, Chen K, Wang J, Shaw K, Eng CMolecular cancer research : MCRComprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal. Mol Cancer Res. 2017 11; 15(11):1542-1550.Mol Cancer Res2017-08-07T00:00:002017Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal.28850629Pereira AAL, Morelli MP, Overman M, Kee B, Fogelman D, Vilar E, Shureiqi I, Raghav K, Eng C, Manuel S, Crosby S, Wolff RA, Banks K, Lanman R, Talasaz A, Kopetz S, Morris VPloS oneClinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One. 2017; 12(8):e0183949.PLoS One2017-08-29T00:00:002017Clinical utility of circulating cell-free DNA in advanced colorectal cancer.29051321M?hrmann L, Huang HJ, Hong DS, Tsimberidou AM, Fu S, Piha-Paul SA, Subbiah V, Karp DD, Naing A, Krug A, Enderle D, Priewasser T, Noerholm M, Eitan E, Coticchia C, Stoll G, Jordan LM, Eng C, Kopetz ES, Skog J, Meric-Bernstam F, Janku FClinical cancer research : an official journal of the American Association for Cancer ResearchLiquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clin Cancer Res. 2018 01 01; 24(1):181-188.Clin Cancer Res2017-10-19T00:00:002017Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers.29114614Gunther JR, Chadha AS, Shin US, Park IJ, Kattepogu KV, Grant JD, Weksberg DC, Eng C, Kopetz SE, Das P, Delclos ME, Kaur H, Maru DM, Skibber JM, Rodriguez-Bigas MA, You YN, Krishnan S, Chang GJAdvances in radiation oncologyPreoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):455-464.Adv Radiat Oncol2017-04-12T00:00:002017Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis.29180604Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz SClinical cancer research : an official journal of the American Association for Cancer ResearchClassifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clin Cancer Res. 2018 03 01; 24(5):1062-1072.Clin Cancer Res2017-11-27T00:00:002017Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes.29184474Ahmed S, Eng CClinics in colon and rectal surgeryNeoadjuvant Strategies: Locally Advanced Rectal Cancer. Clin Colon Rectal Surg. 2017 Nov; 30(5):383-386.Clin Colon Rectal Surg2017-11-27T00:00:002017Neoadjuvant Strategies: Locally Advanced Rectal Cancer.28770514Rogers JE, Eng CDrugsPharmacotherapy of Anal Cancer. Drugs. 2017 Sep; 77(14):1519-1530.Drugs2017-09-01T00:00:002017Pharmacotherapy of Anal Cancer.28831698Sagebiel TL, Mohamed A, Matamoros A, Taggart MW, Doamekpor F, Raghav KP, Mann GN, Mansfield PF, Eng C, Royal RE, Foo WC, Ensor JE, Fournier KF, Overman MJAnnals of surgical oncologyUtility of Appendiceal Calcifications Detected on Computed Tomography as a Predictor for an Underlying Appendiceal Epithelial Neoplasm. Ann Surg Oncol. 2017 Nov; 24(12):3667-3672.Ann Surg Oncol2017-08-22T00:00:002017Utility of Appendiceal Calcifications Detected on Computed Tomography as a Predictor for an Underlying Appendiceal Epithelial Neoplasm.29165790Brusco LL, Wathoo C, Mills Shaw KR, Holla VR, Bailey AM, Johnson AM, Khotskaya YB, Litzenburger BC, Sanchez NS, Zeng J, Bernstam EV, Eng C, Kee BK, Amaria RN, Routbort MJ, Mills GB, Mendelsohn J, Meric-Bernstam FCancerPhysician interpretation of genomic test results and treatment selection. Cancer. 2018 03 01; 124(5):966-972.Cancer2017-11-22T00:00:002017Physician interpretation of genomic test results and treatment selection.28640361Long Y, Sanchez-Espiridion B, Lin M, White L, Mishra L, Raju GS, Kopetz S, Eng C, Hildebrandt MAT, Chang DW, Ye Y, Liang D, Wu XCancerGlobal and targeted serum metabolic profiling of colorectal cancer progression. Cancer. 2017 Oct 15; 123(20):4066-4074.Cancer2017-06-22T00:00:002017Global and targeted serum metabolic profiling of colorectal cancer progression.28695394Grotz TE, Overman MJ, Eng C, Raghav KP, Royal RE, Mansfield PF, Mann GN, Robinson KA, Beaty KA, Rafeeq S, Matamoros A, Taggart MW, Fournier KFAnnals of surgical oncologyCytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection. Ann Surg Oncol. 2017 Sep; 24(9):2646-2654.Ann Surg Oncol2017-07-10T00:00:002017Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection.28759346Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, Lyman GHJournal of clinical oncology : official journal of the American Society of Clinical OncologyAntiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017 Oct 01; 35(28):3240-3261.J Clin Oncol2017-07-31T00:00:002017Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.29084828Mazard T, Boonsirikamchai P, Overman MJ, Asran MA, Choi H, Herron D, Eng C, Maru DM, Ychou M, Vauthey JN, Loyer EM, Kopetz SGutComparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. Gut. 2018 06; 67(6):1095-1102.Gut2017-10-30T00:00:002017Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab.29315288Johnson B, Eng CClinical advances in hematology & oncology : H&OThe promise of immunotherapy in anal squamous cell carcinoma: a novel approach for an orphan disease. Clin Adv Hematol Oncol. 2017 Dec; 15(12):968-961.Clin Adv Hematol Oncol2017-12-01T00:00:002017The promise of immunotherapy in anal squamous cell carcinoma: a novel approach for an orphan disease.29299359Holliday EB, Hunt A, You YN, Chang GJ, Skibber JM, Rodriguez-Bigas MA, Bednarski BK, Eng C, Koay EJ, Minsky BD, Taniguchi C, Krishnan S, Herman JM, Das PJournal of gastrointestinal oncologyShort course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma. J Gastrointest Oncol. 2017 Dec; 8(6):990-997.J Gastrointest Oncol2017-12-01T00:00:002017Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma.29362905Ahmed S, Eng CCurrent oncology reportsRole of Chemotherapy in the Neoadjuvant/Adjuvant Setting for Patients With Rectal Adenocarcinoma Undergoing Chemoradiotherapy and Surgery or Radiotherapy and Surgery. Curr Oncol Rep. 2018 01 23; 20(1):3.Curr Oncol Rep2018-01-23T00:00:002018Role of Chemotherapy in the Neoadjuvant/Adjuvant Setting for Patients With Rectal Adenocarcinoma Undergoing Chemoradiotherapy and Surgery or Radiotherapy and Surgery.29421164Prinsloo S, Novy D, Driver L, Lyle R, Ramondetta L, Eng C, Lopez G, Li Y, Cohen LJournal of pain and symptom managementThe Long-Term Impact of Neurofeedback on Symptom Burden and Interference in Patients With Chronic Chemotherapy-Induced Neuropathy: Analysis of a Randomized Controlled Trial. J Pain Symptom Manage. 2018 05; 55(5):1276-1285.J Pain Symptom Manage2018-02-05T00:00:002018The Long-Term Impact of Neurofeedback on Symptom Burden and Interference in Patients With Chronic Chemotherapy-Induced Neuropathy: Analysis of a Randomized Controlled Trial.29643063Hong DS, Moore K, Patel M, Grant SC, Burris HA, William WN, Jones S, Meric-Bernstam F, Infante J, Golden L, Zhang W, Martinez R, Wijayawardana S, Beckmann R, Lin AB, Eng C, Bendell JClinical cancer research : an official journal of the American Association for Cancer ResearchEvaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. Clin Cancer Res. 2018 07 15; 24(14):3263-3272.Clin Cancer Res2018-04-11T00:00:002018Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.29936065Goey KKH, S?rbye H, Glimelius B, Adams RA, Andr? T, Arnold D, Berlin JD, Bodoky G, de Gramont A, D?az-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman MEuropean journal of cancer (Oxford, England : 1990)Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. Eur J Cancer. 2018 09; 100:35-45.Eur J Cancer2018-06-22T00:00:002018Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.30005993Goumard C, Nancy You Y, Okuno M, Kutlu O, Chen HC, Simoneau E, Vega EA, Chun YS, David Tzeng C, Eng C, Vauthey JN, Conrad CHPB : the official journal of the International Hepato Pancreato Biliary AssociationMinimally invasive management of the entire treatment sequence in patients with stage IV colorectal cancer: a propensity-score weighting analysis. HPB (Oxford). 2018 12; 20(12):1150-1156.HPB (Oxford)2018-07-11T00:00:002018Minimally invasive management of the entire treatment sequence in patients with stage IV colorectal cancer: a propensity-score weighting analysis.30006430Morris VK, Eng CJournal of the National Comprehensive Cancer Network : JNCCNRole of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal. J Natl Compr Canc Netw. 2018 07; 16(7):903-908.J Natl Compr Canc Netw2018-07-01T00:00:002018Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal.29907489Holliday EB, Lester SC, Harmsen WS, Eng C, Haddock MG, Krishnan S, Das P, Hallemeier CLInternational journal of radiation oncology, biology, physicsExtended-Field Chemoradiation Therapy for Definitive Treatment of Anal Canal Squamous Cell Carcinoma Involving the Para-Aortic Lymph Nodes. Int J Radiat Oncol Biol Phys. 2018 09 01; 102(1):102-108.Int J Radiat Oncol Biol Phys2018-05-05T00:00:002018Extended-Field Chemoradiation Therapy for Definitive Treatment of Anal Canal Squamous Cell Carcinoma Involving the Para-Aortic Lymph Nodes.30590946Eng C, Rogers JEExpert opinion on pharmacotherapyCurrent synthetic pharmacotherapy for treatment-resistant colorectal cancer: when urgent action is required. Expert Opin Pharmacother. 2019 Apr; 20(5):523-534.Expert Opin Pharmacother2019-01-08T00:00:002019Current synthetic pharmacotherapy for treatment-resistant colorectal cancer: when urgent action is required.30381968Jacome AA, Eng CExpert opinion on investigational drugsExperimental and investigational drugs for the treatment of anal cancer. Expert Opin Investig Drugs. 2018 12; 27(12):941-950.Expert Opin Investig Drugs2018-11-08T00:00:002018Experimental and investigational drugs for the treatment of anal cancer.30370360Jensen G, Tao R, Eng C, Skibber JM, Rodriguez-Bigas M, Chang GJ, You YN, Bednarski BK, Minsky BD, Koay E, Taniguchi C, Krishnan S, Das PAdvances in radiation oncologyTreatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation. Adv Radiat Oncol. 2018 Oct-Dec; 3(4):595-600.Adv Radiat Oncol2018-07-17T00:00:002018Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation.Authorship 944040528657814Ikoma N, You YN, Bednarski BK, Rodriguez-Bigas MA, Eng C, Das P, Kopetz S, Messick C, Skibber JM, Chang GJJournal of clinical oncology : official journal of the American Society of Clinical OncologyImpact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer. J Clin Oncol. 2017 Aug 10; 35(23):2631-2638.J Clin Oncol2017-06-28T00:00:002017Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer.Authorship 945363131003911Eng C, Kim TW, Bendell J, Argil?s G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F, IMblaze370 InvestigatorsThe Lancet. OncologyAtezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019 06; 20(6):849-861.Lancet Oncol2019-04-16T00:00:002019Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.Authorship 947184131099616Eng C, Messick C, Glynne-Jones RAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual MeetingThe Management and Prevention of Anal Squamous Cell Carcinoma. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:216-225.Am Soc Clin Oncol Educ Book2019-05-17T00:00:002019The Management and Prevention of Anal Squamous Cell Carcinoma.Authorship 950665831243121Lieu CH, Golemis EA, Serebriiskii IG, Newberg J, Hemmerich A, Connelly C, Messersmith WA, Eng C, Eckhardt SG, Frampton G, Cooke M, Meyer JEClinical cancer research : an official journal of the American Association for Cancer ResearchComprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer. Clin Cancer Res. 2019 10 01; 25(19):5852-5858.Clin Cancer Res2019-06-26T00:00:002019Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer.Authorship 951326831254639Wang XS, Shi Q, Bhadkamkar NA, Cleeland CS, Garcia-Gonzalez A, Aguilar JR, Heijnen C, Eng CJournal of pain and symptom managementMinocycline for Symptom Reduction During Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial. J Pain Symptom Manage. 2019 10; 58(4):662-671.J Pain Symptom Manage2019-06-26T00:00:002019Minocycline for Symptom Reduction During Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial.Authorship 952687131350201Eng C, J?come AA, Das P, Chang GJ, Rodriguez-Bigas M, Skibber JM, Wolff RA, Qiao W, Xing Y, Sethi S, Ohinata A, Crane CHClinical colorectal cancerA Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal. Clin Colorectal Cancer. 2019 12; 18(4):301-306.Clin Colorectal Cancer2019-07-02T00:00:002019A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal.Authorship 953114231371229Johnson B, Eng CThe lancet. Gastroenterology & hepatologyMore questions regarding HIPEC in colorectal carcinomatosis. Lancet Gastroenterol Hepatol. 2019 10; 4(10):744-745.Lancet Gastroenterol Hepatol2019-07-29T00:00:002019More questions regarding HIPEC in colorectal carcinomatosis.Authorship 9537451231406299Korphaisarn K, Morris V, Davis JS, Overman MJ, Fogelman DR, Kee BK, Dasari A, Raghav KPS, Shureiqi I, Trupti M, Wolff RA, Eng C, Menter DG, Hamilton S, Kopetz SBritish journal of cancerSignet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer. 2019 09; 121(6):505-510.Br J Cancer2019-08-13T00:00:002019Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma.Authorship 954566231456458Rogers JE, Eng CExpert opinion on pharmacotherapyPharmacotherapeutic considerations for elderly patients with colorectal cancer. Expert Opin Pharmacother. 2019 Dec; 20(17):2139-2160.Expert Opin Pharmacother2019-08-28T00:00:002019Pharmacotherapeutic considerations for elderly patients with colorectal cancer.Authorship 957729131642347J?come AA, Eng CExpert opinion on biological therapyRole of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab. Expert Opin Biol Ther. 2019 12; 19(12):1247-1263.Expert Opin Biol Ther2019-10-23T00:00:002019Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab.Authorship 962802631852833Pairawan S, Hess KR, Janku F, Sanchez NS, Mills Shaw KR, Eng C, Damodaran S, Javle M, Kaseb AO, Hong DS, Subbiah V, Fu S, Fogelman DR, Raymond VM, Lanman RB, Meric-Bernstam FClinical cancer research : an official journal of the American Association for Cancer ResearchCell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res. 2020 04 15; 26(8):1924-1931.Clin Cancer Res2019-12-18T00:00:002019Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer.Authorship 975487431924662Yennurajalingam S, Carmack C, Balachandran D, Eng C, Lim B, Delgado M, Guzman Gutierrez D, Raznahan M, Park M, Hess KR, Williams JL, Lu Z, Ochoa J, Bruera EBMJ supportive & palliative careSleep disturbance in patients with cancer: a feasibility study of multimodal therapy. BMJ Support Palliat Care. 2021 Jun; 11(2):170-179.BMJ Support Palliat Care2020-01-10T00:00:002020Sleep disturbance in patients with cancer: a feasibility study of multimodal therapy.Authorship 976749131999945Eng CThe Lancet. OncologyTAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer? Lancet Oncol. 2020 03; 21(3):326-327.Lancet Oncol2020-01-27T00:00:002020TAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer?Authorship 9863791432243668Al-Shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Meyers BM, Elfiki T, Curigliano G, Eng C, Grothey A, Xie CThe oncologistA Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. Oncologist. 2020 06; 25(6):e936-e945.Oncologist2020-04-27T00:00:002020A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group.Authorship 9882031Authorship 988387432341753Eng C, Fakih M, Amin M, Morris V, Hochster HS, Boland PM, Uronis HOncotargetA phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer. Oncotarget. 2020 Apr 14; 11(15):1334-1343.Oncotarget2020-04-14T00:00:002020A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer.32352884Lou E, Beg S, Bergsland E, Eng C, Khorana A, Kopetz S, Lubner S, Saltz L, Shankaran V, Zafar SYJCO oncology practiceModifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk. JCO Oncol Pract. 2020 07; 16(7):383-388.JCO Oncol Pract2020-04-30T00:00:002020Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk.Authorship 9888343Authorship 9888491432377978Ajani JA, Javle M, Eng C, Fogelman D, Smith J, Anderson B, Zhang C, Iizuka KInvestigational new drugsPhase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors. Invest New Drugs. 2020 12; 38(6):1763-1773.Invest New Drugs2020-05-06T00:00:002020Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors.32378772Coomes EA, Al-Shamsi HO, Meyers BM, Alhazzani W, Alhuraiji A, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Elfiki T, Curigliano G, Eng C, Grothey A, Xie CThe oncologistIn Reply. Oncologist. 2020 08; 25(8):e1252-e1253.Oncologist2020-05-27T00:00:002020In Reply.Authorship 991628332530769Rao S, Sclafani F, Eng C, Adams RA, Guren MG, Sebag-Montefiore D, Benson A, Bryant A, Peckitt C, Segelov E, Roy A, Seymour MT, Welch J, Saunders MP, Muirhead R, O'Dwyer P, Bridgewater J, Bhide S, Glynne-Jones R, Arnold D, Cunningham DJournal of clinical oncology : official journal of the American Society of Clinical OncologyInternational Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. J Clin Oncol. 2020 08 01; 38(22):2510-2518.J Clin Oncol2020-06-12T00:00:002020International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct.Authorship 99183514Authorship 9919116Authorship 992520432536024Coomes EA, Al-Shamsi HO, Meyers BM, Alhazzani W, Alhuraiji A, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Elfiki T, Curigliano G, Eng C, Grothey A, Xie CThe oncologistEvolution of Cancer Care in Response to the COVID-19 Pandemic. Oncologist. 2020 09; 25(9):e1426-e1427.Oncologist2020-07-07T00:00:002020Evolution of Cancer Care in Response to the COVID-19 Pandemic.32540351Holowatyj AN, Washington KM, Salaria SN, Lieu CH, Idrees K, Eng CGastroenterologyEarly-Onset Appendiceal Cancer Survival by Race or Ethnicity in the United States. Gastroenterology. 2020 10; 159(4):1605-1608.Gastroenterology2020-06-13T00:00:002020Early-Onset Appendiceal Cancer Survival by Race or Ethnicity in the United States.32574129Lou E, Beg MS, Bergsland E, Eng C, Khorana AA, Kopetz S, Lubner S, Saltz L, Shankaran V, Zafar SYJCO oncology practiceReply to S. Boutayeb et al. JCO Oncol Pract. 2020 08; 16(8):525.JCO Oncol Pract2020-06-23T00:00:002020Reply to S. Boutayeb et al.Authorship 99372913Authorship 993766632632268Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz SNature reviews. Clinical oncologyctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020 12; 17(12):757-770.Nat Rev Clin Oncol2020-07-06T00:00:002020ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.32634770Demisse R, Damle N, Kim E, Gong J, Fakih M, Eng C, Oesterich L, McKenny M, Ji J, Liu J, Louie R, Tam K, Gholami S, Halabi W, Monjazeb A, Dayyani F, Cho MJournal of the National Comprehensive Cancer Network : JNCCNNeoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series. J Natl Compr Canc Netw. 2020 07; 18(7):798-804.J Natl Compr Canc Netw2020-07-01T00:00:002020Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series.Authorship 99429211Authorship 99437315Authorship 9946181032658626Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Lyman GHJournal of clinical oncology : official journal of the American Society of Clinical OncologyAntiemetics: ASCO Guideline Update. J Clin Oncol. 2020 08 20; 38(24):2782-2797.J Clin Oncol2020-07-13T00:00:002020Antiemetics: ASCO Guideline Update.32665092J?come AA, Kee B, Fogelman D, Dasari A, Shureiqi I, Raghav K, Morris V, Johnson B, Overman M, Wolff R, Kopetz S, Rogers J, Ahmed SU, Mehdizadeh A, Rothschild N, Eng CClinical colorectal cancerFOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clin Colorectal Cancer. 2020 12; 19(4):248-255.e6.Clin Colorectal Cancer2020-06-05T00:00:002020FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival.32680816J?come AA, Ohinata A, Mahvash A, Overman MJ, Kee B, Fogelman D, Morris VK, Johnson B, Rothschild ND, Wolff RA, Eng CClinical colorectal cancerBevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. Clin Colorectal Cancer. 2020 12; 19(4):e189-e199.Clin Colorectal Cancer2020-06-12T00:00:002020Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism.Authorship 9954063Authorship 9957701132733093Raghav K, Shen JP, J?come AA, Guerra JL, Scally CP, Taggart MW, Foo WC, Matamoros A, Shaw KR, Fournier K, Overman MJ, Eng CBritish journal of cancerIntegrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. Br J Cancer. 2020 10; 123(8):1262-1270.Br J Cancer2020-07-31T00:00:002020Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer.32710989Noticewala SS, Ludmir EB, Eng C, Holliday EB, Minsky BD, Morris VK, Das PRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyAnal cancer treatment regimen considerations for the COVID-19 era: In regard to Tchelebi et al. Radiother Oncol. 2020 10; 151:56-57.Radiother Oncol2020-07-22T00:00:002020Anal cancer treatment regimen considerations for the COVID-19 era: In regard to Tchelebi et al.Authorship 9971891032799569Rogers JE, J?come AAA, Ohinata A, Wolff R, Morris VK, Johnson B, Mehdizadeh A, Rothschild ND, Ahmed SU, Guerra JL, Eng CExpert review of anticancer therapyOutcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma. Expert Rev Anticancer Ther. 2020 10; 20(10):901-908.Expert Rev Anticancer Ther2020-09-02T00:00:002020Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma.Authorship 99934114Authorship 999514932923868S?nchez NS, Kahle MP, Bailey AM, Wathoo C, Balaji K, Demirhan ME, Yang D, Javle M, Kaseb A, Eng C, Subbiah V, Janku F, Raymond VM, Lanman RB, Mills Shaw KR, Meric-Bernstam FJCO precision oncologyIdentification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. JCO Precis Oncol. 2019; 3.JCO Precis Oncol2019-09-24T00:00:002019Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA.32914034Johnson B, Loree JM, Jacome AA, Mendis S, Syed M, Morris Ii VK, Parseghian CM, Dasari A, Pant S, Raymond VM, Vilar E, Overman M, Kee B, Eng C, Raghav K, Kopetz SJCO precision oncologyAtypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. JCO Precis Oncol. 2019; 3.JCO Precis Oncol2019-08-05T00:00:002019Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer.Authorship 10050882Authorship 1005268833208919J?come AA, Vreeland TJ, Johnson B, Kawaguchi Y, Wei SH, Nancy You Y, Vilar E, Vauthey JN, Eng CBritish journal of cancerThe prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients. Br J Cancer. 2021 02; 124(4):797-804.Br J Cancer2020-11-19T00:00:002020The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients.33191588Sobrero A, Lenz HJ, Eng C, Scheithauer W, Middleton G, Chen W, Esser R, Nippgen J, Burris HThe oncologistExtended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer. Oncologist. 2021 02; 26(2):e261-e269.Oncologist2020-12-14T00:00:002020Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer.Authorship 10097742Authorship 1009998133503394Eng CJournal of clinical oncology : official journal of the American Society of Clinical OncologyBRAF Mutation in Colorectal Cancer: An Enigmatic Target. J Clin Oncol. 2021 02 01; 39(4):259-261.J Clin Oncol2021-02-01T00:00:002021BRAF Mutation in Colorectal Cancer: An Enigmatic Target.33295976Holowatyj AN, Eng C, Wen W, Idrees K, Guo XJAMA network openSpectrum of Somatic Cancer Gene Variations Among Adults With Appendiceal Cancer by Age at Disease Onset. JAMA Netw Open. 2020 12 01; 3(12):e2028644.JAMA Netw Open2020-12-01T00:00:002020Spectrum of Somatic Cancer Gene Variations Among Adults With Appendiceal Cancer by Age at Disease Onset.Authorship 1010499133534616Eng C, Chen EY, Rogers J, Lewis M, Strosberg J, Thota R, Krishnamurthi S, Oberstein P, Govindarajan R, Buchschacher G, Patel S, Sohal D, Al-Toubah T, Philip P, Dasari A, Kennecke H, Stein SJCO oncology practiceMoving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. JCO Oncol Pract. 2021 10; 17(10):607-614.JCO Oncol Pract2021-02-03T00:00:002021Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation.Authorship 10144072Authorship 1014488233755179Cardin DB, Eng CJournal of the National Cancer InstitutePancreatic Cancer in Young Adults: Can Innovative Approaches Lead to Better Outcomes? J Natl Cancer Inst. 2021 09 04; 113(9):1125-1126.J Natl Cancer Inst2021-09-04T00:00:002021Pancreatic Cancer in Young Adults: Can Innovative Approaches Lead to Better Outcomes?33761808Kam AE, Eng CExpert opinion on biological therapyBRAF V600E mutated metastatic colorectal cancer: current progress and future directions. Expert Opin Biol Ther. 2021 10; 21(10):1311-1313.Expert Opin Biol Ther2021-03-30T00:00:002021BRAF V600E mutated metastatic colorectal cancer: current progress and future directions.Authorship 1015708333795212Gibbs T, Washington MK, Eng C, Idrees K, Davis J, Holowatyj ANCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyHistologic and Racial/Ethnic Patterns of Appendiceal Cancer among Young Patients. Cancer Epidemiol Biomarkers Prev. 2021 06; 30(6):1149-1155.Cancer Epidemiol Biomarkers Prev2021-04-01T00:00:002021Histologic and Racial/Ethnic Patterns of Appendiceal Cancer among Young Patients.Authorship 10170668Authorship 1017413933900857Cimino SK, Ciombor KK, Chakravarthy AB, Bailey CE, Hopkins MB, Geiger TM, Hawkins AT, Eng CExpert opinion on drug safetySafety considerations with new treatment regimens for anal cancer. Expert Opin Drug Saf. 2021 Aug; 20(8):889-902.Expert Opin Drug Saf2021-04-26T00:00:002021Safety considerations with new treatment regimens for anal cancer.33931465Cohen AS, Grudzinski J, Smith GT, Peterson TE, Whisenant JG, Hickman TL, Ciombor KK, Cardin D, Eng C, Goff LW, Das S, Coffey RJ, Berlin JD, Manning HCJournal of nuclear medicine : official publication, Society of Nuclear MedicineFirst-in-Human PET Imaging and Estimated Radiation Dosimetry of l-[5-11C]-Glutamine in Patients with Metastatic Colorectal Cancer. J Nucl Med. 2022 01; 63(1):36-43.J Nucl Med2021-04-30T00:00:002021First-in-Human PET Imaging and Estimated Radiation Dosimetry of l-[5-11C]-Glutamine in Patients with Metastatic Colorectal Cancer.Authorship 10186691033993740Dasari A, Sobrero A, Yao J, Yoshino T, Schelman W, Yang Z, Chien C, Kania M, Tabernero J, Eng CFuture oncology (London, England)FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. Future Oncol. 2021 Aug; 17(24):3151-3162.Future Oncol2021-05-17T00:00:002021FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer.Authorship 1019594934050401Rogers JE, Woodard TL, Dasari A, Kee B, Das P, Bednarski BK, Skibber JM, Rodriguez-Bigas MA, Eng CSupportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerFertility discussions in young adult stage III colorectal cancer population: a single-center institution experience. Support Care Cancer. 2021 Dec; 29(12):7351-7354.Support Care Cancer2021-05-28T00:00:002021Fertility discussions in young adult stage III colorectal cancer population: a single-center institution experience.Authorship 10202421934084278Hester R, Advani S, Rashid A, Holliday E, Messick C, Das P, You YN, Taniguchi C, Koay EJ, Bednarski B, Rodriguez-Bigas M, Skibber J, Wolff R, Chang GJ, Minsky BD, Foo WC, Rothschild N, Morris VK, Eng COncotargetCEA as a blood-based biomarker in anal cancer. Oncotarget. 2021 May 25; 12(11):1037-1045.Oncotarget2021-05-25T00:00:002021CEA as a blood-based biomarker in anal cancer.Authorship 1020561434092493Livingston AJ, Bailey CE, Washington MK, Eng CClinical colorectal cancerSquamous Cell Carcinoma of the Anal Verge with Sigmoid Colon Metastasis. Clin Colorectal Cancer. 2021 09; 20(3):e210-e213.Clin Colorectal Cancer2021-05-05T00:00:002021Squamous Cell Carcinoma of the Anal Verge with Sigmoid Colon Metastasis.Authorship 10212451534132476Arhin ND, Shen C, Bailey CE, Matsuoka LK, Hawkins AT, Holowatyj AN, Ciombor KK, Hopkins MB, Geiger TM, Kam AE, Roth MT, Lebeck Lee CM, Lapelusa M, Dasari A, Eng CCancer medicineSurgical resection and survival outcomes in metastatic young adult colorectal cancer patients. Cancer Med. 2021 07; 10(13):4269-4281.Cancer Med2021-06-16T00:00:002021Surgical resection and survival outcomes in metastatic young adult colorectal cancer patients.Authorship 1027944134405226Eng C, Hochster HJournal of the National Cancer InstituteEarly-Onset Colorectal Cancer: The Mystery Remains. J Natl Cancer Inst. 2021 Nov 29; 113(12):1608-1610.J Natl Cancer Inst2021-11-29T00:00:002021Early-Onset Colorectal Cancer: The Mystery Remains.Authorship 1030225234554830Holowatyj AN, Eng C, Lewis MAJCO oncology practiceIncorporating Reproductive Health in the Clinical Management of Early-Onset Colorectal Cancer. JCO Oncol Pract. 2022 03; 18(3):169-172.JCO Oncol Pract2021-09-23T00:00:002021Incorporating Reproductive Health in the Clinical Management of Early-Onset Colorectal Cancer.Authorship 1032281434690067Lebeck Lee C, Zwerner J, O'Brian B, Eng CClinical colorectal cancerCutaneous Lymphangitic Carcinomatosis as the First Sign of Recurrent Malignancy in a Patient With a History of Rectal Adenocarcinoma. Clin Colorectal Cancer. 2021 12; 20(4):368-371.Clin Colorectal Cancer2021-09-26T00:00:002021Cutaneous Lymphangitic Carcinomatosis as the First Sign of Recurrent Malignancy in a Patient With a History of Rectal Adenocarcinoma.Authorship 1034632234847242Tchelebi LT, Eng C, Messick CA, Hong TS, Ludmir EB, Kachnic LA, Zaorsky NGCA: a cancer journal for cliniciansCurrent treatment and future directions in the management of anal cancer. CA Cancer J Clin. 2022 03; 72(2):183-195.CA Cancer J Clin2021-11-30T00:00:002021Current treatment and future directions in the management of anal cancer.Authorship 1034956434865086Goldberg RM, Adams R, Buyse M, Eng C, Grothey A, Andr? T, Sobrero AF, Lichtman SM, Benson AB, Punt CJA, Maughan T, Burzykowski T, Sommeijer D, Saad ED, Shi Q, Coart E, Chibaudel B, Koopman M, Schmoll HJ, Yoshino T, Taieb J, Tebbutt NC, Zalcberg J, Tabernero J, Van Cutsem E, Matheson A, de Gramont AJournal of the National Cancer InstituteClinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. J Natl Cancer Inst. 2022 06 13; 114(6):819-828.J Natl Cancer Inst2022-06-13T00:00:002022Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology.Authorship 10383068Authorship 10383332Authorship 10383341Authorship 10383352Authorship 10385644Authorship 103861515Authorship 10390831Authorship 10394693Authorship 10402401035305097Holliday EB, Morris VK, Johnson B, Eng C, Ludmir EB, Das P, Minsky BD, Taniguchi C, Smith GL, Koay EJ, Koong AC, Delclos ME, Skibber JM, Rodriguez-Bigas MA, You YN, Bednarski BK, Tillman MM, Chang GJ, Jennings K, Messick CAThe oncologistDefinitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. Oncologist. 2022 02 03; 27(1):40-47.Oncologist2022-02-03T00:00:002022Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution.35308916Peterson SK, Basen-Engquist K, Demark-Wahnefried W, Prokhorov AV, Shinn EH, Martch SL, Beadle BM, Garden AS, Farcas E, Brandon Gunn G, Fuller CD, Morrison WH, Rosenthal DI, Phan J, Eng C, Cinciripini PM, Karam-Hage MA, Camero Garcia M, Patrick KAMIA ... Annual Symposium proceedings. AMIA SymposiumFeasibility of Mobile and Sensor Technology for Remote Monitoring in Cancer Care and Prevention. AMIA Annu Symp Proc. 2021; 2021:979-988.AMIA Annu Symp Proc2022-02-21T00:00:002022Feasibility of Mobile and Sensor Technology for Remote Monitoring in Cancer Care and Prevention.35125320Miranda KW, Cimino SK, Eng CClinical colorectal cancerTargeted Fibroblast Growth Factor Receptor (FGFR) Inhibition in Recurrent, Metastatic Anal Carcinoma: A Case Report. Clin Colorectal Cancer. 2022 09; 21(3):272-275.Clin Colorectal Cancer2022-01-20T00:00:002022Targeted Fibroblast Growth Factor Receptor (FGFR) Inhibition in Recurrent, Metastatic Anal Carcinoma: A Case Report.35090673Eng C, J?come AA, Agarwal R, Hayat MH, Byndloss MX, Holowatyj AN, Bailey C, Lieu CHThe Lancet. OncologyA comprehensive framework for early-onset colorectal cancer research. Lancet Oncol. 2022 03; 23(3):e116-e128.Lancet Oncol2022-01-31T00:00:002022A comprehensive framework for early-onset colorectal cancer research.35285949Lebeck Lee CM, Ziogas IA, Agarwal R, Alexopoulos SP, Ciombor KK, Matsuoka LK, Brown DB, Eng CCancerA contemporary systematic review on liver transplantation for unresectable liver metastases of colorectal cancer. Cancer. 2022 06 15; 128(12):2243-2257.Cancer2022-03-14T00:00:002022A contemporary systematic review on liver transplantation for unresectable liver metastases of colorectal cancer.35289787Hubbard JM, Eng C, Cremolini C, Marshall JLClinical advances in hematology & oncology : H&OConsiderations in the management of younger patients with colorectal cancer. Clin Adv Hematol Oncol. 2021 Jun; 19 Suppl 16(6):1-20.Clin Adv Hematol Oncol2021-06-01T00:00:002021Considerations in the management of younger patients with colorectal cancer.35289788Eng CClinical advances in hematology & oncology : H&OExamining the increase in colorectal cancer in younger patients. Clin Adv Hematol Oncol. 2021 Jun; 19 Suppl 16(6):3-6.Clin Adv Hematol Oncol2021-06-01T00:00:002021Examining the increase in colorectal cancer in younger patients.35289792Hubbard JM, Eng C, Cremolini C, Marshall JLClinical advances in hematology & oncology : H&OConsiderations in the management of younger patients With colorectal cancer: Q&A. Clin Adv Hematol Oncol. 2021 06; 19 Suppl 16(6):15-17.Clin Adv Hematol Oncol2021-06-01T00:00:002021Considerations in the management of younger patients With colorectal cancer: Q&A.35053447LaPelusa M, Shen C, Arhin ND, Cardin D, Tan M, Idrees K, Geevarghese S, Chakravarthy B, Berlin J, Eng CCancersTrends in the Incidence and Treatment of Early-Onset Pancreatic Cancer. Cancers (Basel). 2022 Jan 07; 14(2).Cancers (Basel)2022-01-07T00:00:002022Trends in the Incidence and Treatment of Early-Onset Pancreatic Cancer.18936472Blazer DG, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, Curley SA, Abdalla EK, Vauthey JNJournal of clinical oncology : official journal of the American Society of Clinical OncologyPathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008 Nov 20; 26(33):5344-51.J Clin Oncol2008-10-20T00:00:002008Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.15849507Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Curley SA, Loyer EM, Muratore A, Mentha G, Capussotti L, Vauthey JNAnnals of surgeryEffect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005 May; 241(5):715-22, discussion 722-4.Ann Surg2005-05-01T00:00:002005Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases.17960603Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C, Chang DZ, Curley SA, Abdalla EK, Ellis LM, Vauthey JNCancerBevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007 Dec 15; 110(12):2761-7.Cancer2007-12-15T00:00:002007Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases.Authorship 10448611Authorship 10451861735491647Eng C, Holowatyj ANCancer discoveryColorectal Cancer Genomics by Genetic Ancestry. Cancer Discov. 2022 05 02; 12(5):1187-1188.Cancer Discov2022-05-02T00:00:002022Colorectal Cancer Genomics by Genetic Ancestry.35513187Lin D, El Alam MB, Jaoude JA, Kouzy R, Phan JL, Elnaggar JH, Resendiz B, Medrano AYD, Lynn EJ, Nguyen ND, Noticewala SS, Mathew GG, Holliday EB, Minsky BD, Das P, Morris VK, Eng C, Mezzari MP, Petrosino JF, Ajami NJ, Klopp AH, Taniguchi CM, Colbert LEInternational journal of radiation oncology, biology, physicsMicrobiome Dynamics During Chemoradiation Therapy for Anal Cancer. Int J Radiat Oncol Biol Phys. 2022 08 01; 113(5):974-984.Int J Radiat Oncol Biol Phys2022-05-02T00:00:002022Microbiome Dynamics During Chemoradiation Therapy for Anal Cancer.21263087Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JNJournal of clinical oncology : official journal of the American Society of Clinical OncologyHigh survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011 Mar 10; 29(8):1083-90.J Clin Oncol2011-01-24T00:00:002011High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome.16648507Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EKJournal of clinical oncology : official journal of the American Society of Clinical OncologyChemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006 May 01; 24(13):2065-72.J Clin Oncol2006-05-01T00:00:002006Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.Authorship 10458851035557581Morris V, Kee B, Overman M, Dasari A, Raghav K, Johnson B, Parseghian C, Wolff RA, Garg N, Eng C, Kopetz SJournal of gastrointestinal oncologyClinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. J Gastrointest Oncol. 2022 Apr; 13(2):647-656.J Gastrointest Oncol2022-04-01T00:00:002022Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer.Authorship 1046500535608860Shen C, Tannenbaum D, Horn R, Rogers J, Eng C, Zhou S, Johnson B, Kopetz S, Morris V, Overman M, Parseghian C, Chang GJ, Lopez-Olivo MA, Kanwal R, Ellis LM, Dasari AJAMA network openOverall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review. JAMA Netw Open. 2022 05 02; 5(5):e2213588.JAMA Netw Open2022-05-02T00:00:002022Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review.Authorship 1047024135649196Eng C, Ciombor KK, Cho M, Dorth JA, Rajdev LN, Horowitz DP, Gollub MJ, J?come AA, Lockney NA, Muldoon RL, Washington MK, O'Brian BA, Benny A, Lebeck Lee CM, Benson AB, Goodman KA, Morris VKJournal of clinical oncology : official journal of the American Society of Clinical OncologyAnal Cancer: Emerging Standards in a Rare Disease. J Clin Oncol. 2022 08 20; 40(24):2774-2788.J Clin Oncol2022-06-01T00:00:002022Anal Cancer: Emerging Standards in a Rare Disease.Authorship 1047680235666353J?come AA, Morris VK, Eng CCurrent treatment options in oncologyThe Role of Immunotherapy in the Treatment of Anal Cancer and Future Strategies. Curr Treat Options Oncol. 2022 08; 23(8):1073-1085.Curr Treat Options Oncol2022-06-06T00:00:002022The Role of Immunotherapy in the Treatment of Anal Cancer and Future Strategies.Authorship 10508711435845232Rogers JE, Woodard TL, Gonzalez GM, Dasari A, Johnson B, Morris VK, Kee B, Vilar E, Nancy You Y, Chang GJ, Bednarski B, Skibber JM, Rodriguez-Bigas MA, Eng CObstetric medicineColorectal cancer during pregnancy or postpartum: Case series and literature review. Obstet Med. 2022 Jun; 15(2):118-124.Obstet Med2021-09-07T00:00:002021Colorectal cancer during pregnancy or postpartum: Case series and literature review.Authorship 1051484835892891LaPelusa M, Shen C, Gillaspie EA, Cann C, Lambright E, Chakravarthy AB, Gibson MK, Eng CCancersVariation in Treatment Patterns of Patients with Early-Onset Gastric Cancer. Cancers (Basel). 2022 Jul 26; 14(15).Cancers (Basel)2022-07-26T00:00:002022Variation in Treatment Patterns of Patients with Early-Onset Gastric Cancer.Authorship 10590482Authorship 106034312Authorship 10562117Authorship 105993821Authorship 105455216Authorship 106244024Authorship 10621272Authorship 1055630836252154Morris VK, Kennedy EB, Baxter NN, Benson AB, Cercek A, Cho M, Ciombor KK, Cremolini C, Davis A, Deming DA, Fakih MG, Gholami S, Hong TS, Jaiyesimi I, Klute K, Lieu C, Sanoff H, Strickler JH, White S, Willis JA, Eng CJournal of clinical oncology : official journal of the American Society of Clinical OncologyTreatment of Metastatic Colorectal Cancer: ASCO Guideline. J Clin Oncol. 2023 01 20; 41(3):678-700.J Clin Oncol2022-10-17T00:00:002022Treatment of Metastatic Colorectal Cancer: ASCO Guideline.36636059Gunther JR, Chadha AS, Guha S, Raju GS, Maru DM, Munsell MF, Jiang Y, Yang P, Felix E, Clemons M, Mathew GG, Singh PK, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Eng C, Delclos ME, Crane CH, Das P, Krishnan SJournal of gastrointestinal oncologyA phase II randomized double blinded trial evaluating the efficacy of curcumin with pre-operative chemoradiation for rectal cancer. J Gastrointest Oncol. 2022 Dec; 13(6):2938-2950.J Gastrointest Oncol2022-12-01T00:00:002022A phase II randomized double blinded trial evaluating the efficacy of curcumin with pre-operative chemoradiation for rectal cancer.36348045Lopez G, Eng C, Overman M, Ramirez D, Liu W, Beinhorn C, Sumler P, Prinsloo S, Li Y, Chen M, Bruera E, Cohen LScientific reportsA randomized pilot study of oncology massage to treat chemotherapy-induced peripheral neuropathy. Sci Rep. 2022 11 08; 12(1):19023.Sci Rep2022-11-08T00:00:002022A randomized pilot study of oncology massage to treat chemotherapy-induced peripheral neuropathy.36623236Ciombor KK, Eng CJournal of clinical oncology : official journal of the American Society of Clinical OncologyImmunotherapy in Localized Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors: Are We Ready for a New Standard of Care? J Clin Oncol. 2023 04 20; 41(12):2138-2140.J Clin Oncol2023-01-09T00:00:002023Immunotherapy in Localized Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors: Are We Ready for a New Standard of Care?36520636Holowatyj AN, Wen W, Gibbs T, Seagle HM, Keller SR, Edwards DRV, Washington MK, Eng C, Perea J, Zheng W, Guo XCancer discoveryRacial/Ethnic and Sex Differences in Somatic Cancer Gene Mutations among Patients with Early-Onset Colorectal Cancer. Cancer Discov. 2023 03 01; 13(3):570-579.Cancer Discov2023-03-01T00:00:002023Racial/Ethnic and Sex Differences in Somatic Cancer Gene Mutations among Patients with Early-Onset Colorectal Cancer.35912589J?come AA, Peixoto RD, Gil MV, Ominelli J, Prolla G, Dienstmann R, Eng CExpert opinion on biological therapyBiologics in rectal cancer. Expert Opin Biol Ther. 2022 10; 22(10):1245-1257.Expert Opin Biol Ther2022-08-03T00:00:002022Biologics in rectal cancer.36549470Cavestro GM, Mannucci A, Balaguer F, Hampel H, Kupfer SS, Repici A, Sartore-Bianchi A, Sepp?l? TT, Valentini V, Boland CR, Brand RE, Buffart TE, Burke CA, Caccialanza R, Cannizzaro R, Cascinu S, Cercek A, Crosbie EJ, Danese S, Dekker E, Daca-Alvarez M, Deni F, Dominguez-Valentin M, Eng C, Goel A, Guillem JG, Houwen BBSL, Kahi C, Kalady MF, Kastrinos F, K?hn F, Laghi L, Latchford A, Liska D, Lynch P, Malesci A, Mauri G, Meldolesi E, M?ller P, Monahan KJ, M?slein G, Murphy CC, Nass K, Ng K, Oliani C, Papaleo E, Patel SG, Puzzono M, Remo A, Ricciardiello L, Ripamonti CI, Siena S, Singh SK, Stadler ZK, Stanich PP, Syngal S, Turi S, Urso ED, Valle L, Vanni VS, Vilar E, Vitellaro M, You YN, Yurgelun MB, Zuppardo RA, Stoffel EM, Associazione Italiana Familiarit? Ereditariet? Tumori, Collaborative Group of the Americas on Inherited Gastrointestinal Cancer, European Hereditary Tumour Group, and the International Society for Gastrointestinal Hereditary TumoClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationDelphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines. Clin Gastroenterol Hepatol. 2023 03; 21(3):581-603.e33.Clin Gastroenterol Hepatol2022-12-20T00:00:002022Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines.36007963Johnson B, Haymaker CL, Parra ER, Soto LMS, Wang X, Thomas JV, Dasari A, Morris VK, Raghav K, Vilar E, Kee BK, Eng C, Parseghian CM, Wolff RA, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba II, Futreal A, Kopetz S, Overman MJJournal for immunotherapy of cancerPhase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer. 2022 08; 10(8).J Immunother Cancer2022-08-01T00:00:002022Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).Authorship 10649981136867316Jimeno A, Baranda J, Iams WT, Park JC, Mita M, Gordon MS, Taylor M, Dhani N, Leal AD, Neupane P, Eng C, Yeku O, Mita A, Moser JC, Butler M, Loughhead SM, Jennings J, Miselis NR, Ji RR, Nair N, Kornacker M, Zwirtes RF, Bernstein H, Sharei AInvestigational new drugsPhase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors. Invest New Drugs. 2023 04; 41(2):284-295.Invest New Drugs2023-03-03T00:00:002023Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors.Authorship 10668742Authorship 10669531932825640Roth MT, Eng CCancersNeoadjuvant Chemotherapy for Colon Cancer Cancers (Basel). 2020 09 26; 12(9).Cancers (Basel)2020-09-26T00:00:002020Neoadjuvant Chemotherapy for Colon Cancer36980587Hernandez S, Das P, Holliday EB, Shen L, Lu W, Johnson B, Messick CA, Taniguchi CM, Skibber J, Ludmir EB, You YN, Smith GL, Bednarski B, Kostousov L, Koay EJ, Minsky BD, Tillman M, Portier S, Eng C, Koong AC, Chang GJ, Foo WC, Wang J, Soto LS, Morris VKCancersDifferential Spatial Gene and Protein Expression Associated with Recurrence Following Chemoradiation for Localized Anal Squamous Cell Cancer. Cancers (Basel). 2023 Mar 10; 15(6).Cancers (Basel)2023-03-10T00:00:002023Differential Spatial Gene and Protein Expression Associated with Recurrence Following Chemoradiation for Localized Anal Squamous Cell Cancer.Authorship 1067866537114458Janczewski LM, Faski J, Nelson H, Gollub MJ, Eng C, Brierley JD, Palefsky JM, Goldberg RM, Washington MK, Asare EA, Goodman KA, American Joint Committee on Cancer Expert Panel on Cancers of the Lower Gastrointestinal, Anus DiseaCA: a cancer journal for cliniciansSurvival outcomes used to generate version 9 American Joint Committee on Cancer staging system for anal cancer. CA Cancer J Clin. 2023 Sep-Oct; 73(5):516-523.CA Cancer J Clin2023-04-28T00:00:002023Survival outcomes used to generate version 9 American Joint Committee on Cancer staging system for anal cancer.Authorship 107359611Authorship 10740964Authorship 10728962Authorship 10740125Authorship 10743153737221249Lopez G, Eng C, Overman M, Ramirez D, Liu W, Beinhorn C, Sumler P, Prinsloo S, Li Y, Chen M, Bruera E, Cohen LScientific reportsPublisher Correction: A randomized pilot study of oncology massage to treat chemotherapy-induced peripheral neuropathy. Sci Rep. 2023 May 23; 13(1):8318.Sci Rep2023-05-23T00:00:002023Publisher Correction: A randomized pilot study of oncology massage to treat chemotherapy-induced peripheral neuropathy.37286304Kelly RJ, Bever K, Chao J, Ciombor KK, Eng C, Fakih M, Goyal L, Hubbard J, Iyer R, Kemberling HT, Krishnamurthi S, Ku G, Mordecai MM, Morris VK, Paulson AS, Peterson V, Shah MA, Le DTJournal for immunotherapy of cancerSociety for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer. J Immunother Cancer. 2023 06; 11(6).J Immunother Cancer2023-06-01T00:00:002023Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer.37261831Shen JP, Yousef AM, Zeineddine FA, Zeineddine MA, Tidwell RS, Beaty KA, Scofield LC, Rafeeq S, Hornstein N, Lano E, Eng C, Matamoros A, Foo WC, Uppal A, Scally C, Mansfield P, Taggart M, Raghav KP, Overman MJ, Fournier KJAMA network openEfficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial. JAMA Netw Open. 2023 06 01; 6(6):e2316161.JAMA Netw Open2023-06-01T00:00:002023Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial.37409250Cann CG, LaPelusa MB, Cimino SK, Eng CFrontiers in oncologyMolecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements. Front Oncol. 2023; 13:1176950.Front Oncol2023-06-20T00:00:002023Molecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements.37331369Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, Garc?a-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csoszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C, FRESCO-2 Study InvestigatorsLancet (London, England)Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023 07 01; 402(10395):41-53.Lancet2023-06-15T00:00:002023Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.Authorship 10791698Authorship 1077258637568706Rogers JE, Sirisaengtaksin A, Leung M, Morris VK, Xiao L, Huey R, Wolff R, Eng C, Vauthey JN, Tzeng CD, Johnson BCancersHepatic Metastasectomy in Squamous Cell Carcinoma of the Anal Canal: A Case Series of a Curative Approach. Cancers (Basel). 2023 Jul 31; 15(15).Cancers (Basel)2023-07-31T00:00:002023Hepatic Metastasectomy in Squamous Cell Carcinoma of the Anal Canal: A Case Series of a Curative Approach.37535679Kennecke HF, Auer R, Cho M, Dasari NA, Davies-Venn C, Eng C, Dorth J, Garcia-Aguilar J, George M, Goodman KA, Kreppel L, Meyer JE, Monzon J, Saltz L, Schrag D, Smith JJ, Zell JA, Das P, National Cancer Institute Rectal-Anal Task ForceJournal of the National Cancer InstituteNCI Rectal-Anal Task Force consensus recommendations for design of clinical trials in rectal cancer. J Natl Cancer Inst. 2023 12 06; 115(12):1457-1464.J Natl Cancer Inst2023-12-06T00:00:002023NCI Rectal-Anal Task Force consensus recommendations for design of clinical trials in rectal cancer.Authorship 1084611737963306Santos ES, Oliver TK, Lacchetti C, Geisel R, Wilfong LS, Fader AN, Eng CJCO oncology practiceDrug Shortages in Oncology: ASCO Clinical Guidance for Alternative Treatments. JCO Oncol Pract. 2024 Jan; 20(1):19-32.JCO Oncol Pract2023-11-14T00:00:002023Drug Shortages in Oncology: ASCO Clinical Guidance for Alternative Treatments.Authorship 10850274Authorship 1085410838140735Janczewski LM, Browner A, Cotler J, Nelson H, Ballman KV, LeBlanc M, Gollub MJ, Eng C, Brierley JD, Palefsky JM, Goldberg RM, Goodman KA, Washington MK, Asare EA, Palis BCancerData-driven optimization of version 9 American Joint Committee on Cancer staging system for anal cancer. Cancer. 2023 Dec 22.Cancer2023-12-22T00:00:002023Data-driven optimization of version 9 American Joint Committee on Cancer staging system for anal cancer.38103030LaPelusa M, Cann C, Ciombor KK, Eng CThe oncologistMutational Signature Changes in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. Oncologist. 2023 Dec 16.Oncologist2023-12-16T00:00:002023Mutational Signature Changes in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessor24799976Rogers JE, Crane CH, Das P, Delclos M, Gould MS, Ohinata A, Malatek D, Eng CGastrointestinal cancer research : GCRDefinitive chemoradiation in oligometastatic squamous cell carcinoma of the anal canal. Gastrointest Cancer Res. 2014 Mar; 7(2):65-8.Gastrointest Cancer Res2014-03-01T00:00:002014Definitive chemoradiation in oligometastatic squamous cell carcinoma of the anal canal.16598762Hoff PM, Wolff RA, Xiong H, Jones D, Lin E, Eng C, Dutta A, Bogaard KR, Abbruzzese JLCancerPhase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer. Cancer. 2006 May 15; 106(10):2241-6.Cancer2006-05-15T00:00:002006Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer.